1-1-2011

Mechanisms of Brain Region-Specific Amyloid-beta Deposition

Adam Bero
Washington University in St. Louis

Follow this and additional works at: http://openscholarship.wustl.edu/etd

Recommended Citation
Mechanisms of Brain Region-Specific Amyloid-β Deposition

by

Adam William Bero

A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy

December 2011

Saint Louis, Missouri
copyright by

Adam William Bero

2011
ABSTRACT OF THE DISSERTATION

Mechanisms of Brain Region-Specific Amyloid-β Deposition

by

Adam William Bero

Doctor of Philosophy in Neurosciences

Washington University in St. Louis, 2011

David M. Holtzman, M.D., Chairperson

Alzheimer’s disease (AD) is the most common cause of dementia. A fundamental feature of AD is brain region-specific deposition of extracellular amyloid plaques principally comprised of the amyloid-β (Aβ) peptide. Using mouse models of cerebral Aβ deposition, we examined molecular, cellular and systems-level mechanisms that regulate brain region-specific Aβ accumulation and aggregation. Parallel studies using in vivo multiphoton microscopy and in vivo microdialysis revealed that modest pharmacological reduction of soluble interstitial fluid (ISF) Aβ levels was associated with a dramatic reduction in amyloid plaque formation and growth. We found that ISF Aβ concentrations in several brain regions of APP transgenic mice prior to the onset of plaque deposition were proportional to the degree of subsequent plaque deposition and with the concentration of lactate, a marker of neuronal activity. Moreover, we found that physiological modulation of endogenous neuronal activity by vibrissal manipulation was sufficient to modulate ISF Aβ levels and amyloid plaque growth dynamics. Using a
novel optical intrinsic signal imaging approach, we found that bilateral functional connectivity magnitude in APP/PS1 mice prior to plaque deposition was proportional to the amount of regional plaque deposition in aged APP/PS1 mice. Furthermore, we found that bilateral functional connectivity was reduced in normal aging and was markedly exacerbated by Aβ deposition. Together, these data suggest that endogenous neuronal activity and functional connectivity may regulate region-specific Aβ plaque deposition. These data advance our understanding of the mechanisms by which the intrinsic metabolic and functional organization of the brain may contribute to AD pathogenesis.
Acknowledgements

I would first like to acknowledge the enthusiastic support and guidance I have received from my mentor, David Holtzman, throughout the duration of my thesis work. Dave, it has been an honor to count myself as a graduate student in your lab. Thanks for everything.

I would like to thank the National Institutes of Health and the Hope Center for Neurological Disorders at Washington University School of Medicine for generous financial support of the work described herein.

I am indebted to all members of my thesis committee for their valuable contributions to the experiments described herein as well as my professional and scientific development. Specifically, Marc Raichle has inspired me to think beyond disciplinary boundaries and our discussions never failed to lift my spirits.

I am also grateful for the mentorship I received from Dr. Cara Wellman during my undergraduate career at Indiana University. Cara served as my Honors Thesis mentor at IU and holds the (perhaps dubious) distinction of sparking my interest in basic neuroscience research.

To the members of the Holtzman lab, thank you for the conversations, the arguments and the laughs. Joe and Philip, I will miss our discussions (both academic and absurd) and our nights spent “celebrating”. Cheers, Goodfellows.

The friendships I have made during my graduate student career have lessened the collective blow of many failed experiments. Until the day amyloid deposits overwhelm
my cognitive reserve, I will not forget the holiday parties, the float trips or the impromptu happy hours.

To Cailin, our relationship has meant the world to me. Over the last 5 years, you have made every good moment better and every bad moment tolerable. I love you.

The unconditional love and support of my family has been a constant in my life. My parents instilled in me the value of a strong work ethic and self-belief that have catalyzed my academic success. And Zack, thanks for helping to preserve my humility and what remains of my social aptitude. I dedicate this thesis to my family.
# Table of Contents

Abstract of the dissertation ................................................................. ii
Acknowledgements .............................................................................. iv
Table of Contents ................................................................................ vi
Figure list ............................................................................................ viii
Publication list ..................................................................................... xi

## Chapter 1. Introduction and Perspective

Alzheimer’s disease .............................................................................. 2
Amyloid-β peptide and amyloid plaque deposition ............................. 3
Mouse models of Aβ plaque deposition .............................................. 5
Neuronal activity and ISF Aβ metabolism ......................................... 7
Default-mode network and Aβ deposition ......................................... 9
Functional connectivity and Aβ deposition ....................................... 11

## Chapter 2. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice

Preface ................................................................................................. 14
Abstract .............................................................................................. 15
Introduction .......................................................................................... 16
Materials and Methods ...................................................................... 18
Results .................................................................................................. 25
Discussion ............................................................................................. 30
Figures ................................................................................................... 34

## Chapter 3. Neuronal activity regulates the regional vulnerability to amyloid-β deposition

Preface ................................................................................................. 52
Abstract .............................................................................................. 53
Introduction .......................................................................................... 54
Materials and Methods ...................................................................... 56
Results .................................................................................................. 65
Discussion ............................................................................................. 75
Chapter 4. Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain

Preface .................................................................................................................................96
Abstract ...............................................................................................................................97
Introduction ..........................................................................................................................98
Materials and Methods ......................................................................................................100
Results .................................................................................................................................106
Discussion ...........................................................................................................................110
Figures .................................................................................................................................114

Chapter 5. Conclusions and future directions

Summary ...............................................................................................................................122
Super-resolution examination of AD pathogenesis .........................................................125
Mechanisms of functional connectivity disruption in AD ..............................................127
Concluding remarks ..........................................................................................................130

References ..........................................................................................................................131
2.1 Serial *in vivo* multiphoton microscopy demonstrates growth of individual amyloid plaques..........................................................................................34

2.2 Amyloid plaques exhibit age- and size-related growth under thinned-skull window preparations..................................................................................35

2.3 Open-skull cranial window preparations are associated with extensive gliosis..............................................................................................................37

2.4 γ-secretase inhibition suppresses plaque growth and new plaque formation........................................................................................................39

2.5 γ-secretase inhibition reduces plaque load in 6 month-old APP/PS1 mice........................................................................................................41

2.6 γ-secretase inhibition results in modest decreases in ISF Aβ levels in cortex........................................................................................................42

S2.1 Schematic representation of open- and thinned-skull cranial window preparations.................................................................................................44

S2.2 Laser power does not affect plaque size determination..............................................................................................................................45

S2.3 Ten month-old APP/PS1 mice do not exhibit significant average plaque growth................................................................................................47

S2.4 Frequency distribution plots indicate that plaque growth dynamics are related to animal age and skull window preparation.....................................................................48

S2.5 γ-secretase inhibition does not alter plaque growth in 10 month-old APP/PS1 mice.........................................................................................49

S2.6 Compound E transiently reduces ISF Aβ concentration..............................................................................................................................50

3.1 Distribution of Aβ and amyloid plaque deposition in Tg2576 mouse brain..................80
3.2 Steady-state ISF Aβ concentrations in young Tg2576 mice before plaque deposition are associated with the level of region-specific plaque deposition in aged Tg2576 mice

3.3 Neuronal activity regulates ISF lactate concentration in vivo

3.4 Steady-state ISF lactate levels in young Tg2576 mice are closely associated with regional ISF Aβ levels in young Tg2576 mice and plaque deposition in aged Tg2576 mice

3.5 Vibrissal activity regulates ISF Aβ levels in vivo

3.6 Diurnal fluctuation of ISF Aβ is closely associated with ISF lactate levels

3.7 Vibrissal deprivation reduces amyloid plaque growth and formation in vivo

S3.1 Regional ISF Aβ and lactate levels in wild-type (B6SJL) mice

S3.2 Time course of picrototoxin and tetrodotoxin treatment on ISF $A\beta_{x-40}$ and lactate levels in hippocampus

S3.3 ISF $A\beta_{x-40}$ clearance rates across brain regions of young Tg2576 mouse brain

S3.4 APP expression and processing are not associated with regional ISF Aβ levels or plaque deposition

S3.5 Glial activation in barrel cortex following long-term vibrissae deprivation

4.1 fcOIS reveals regional differences in bilateral functional connectivity magnitude in APP/PS1 mice prior to Aβ plaque deposition

4.2 fcOIS reveals regional differences in bilateral functional connectivity magnitude in young wild-type mice

4.3 Regional bilateral functional connectivity magnitude in young APP/PS1
mice is closely associated with regional plaque deposition in older
APP/PS1 mice .............................................................................................................116
4.4 Aβ plaque deposition is associated with decreased functional
connectivity magnitude in multiple brain systems of older APP/PS1 mice..............118
4.5 Normal aging is associated with decreased functional connectivity
magnitude in retrosplenial cortex..................................................................................119
4.6 Regional Aβ plaque deposition is associated with degree of age-related
decline in bilateral functional connectivity..................................................................120
Publication list

   *These authors contributed equally to this work


   *These authors contributed equally to this work

Chapter 1.

Introduction and perspective


Alzheimer’s disease

Alzheimer’s disease (AD) is the most common cause of dementia. It is estimated that over 26 million individuals worldwide suffer from AD, including over 10% of individuals ≥ 65 years of age and nearly 50% of individuals ≥ 85 years of age (Thies and Bleiler, 2011). Given that no treatment that halts or reverses the progression of AD is available, and that the number of AD cases and associated costs are projected to quadruple by the year 2050, a greater understanding of the molecular mechanisms of AD pathogenesis is urgently needed.

Short-term memory dysfunction is an early and essential feature of cognitive decline in AD. At initial clinical presentation, short-term memory dysfunction is typically accompanied by deficits in executive function, attention and problem-solving. As the disease progresses into successive stages of severity, changes such as personality alteration, language dysfunction and a reduced capacity to perform activities of daily living gradually emerge. Following the onset of clinical symptoms, the time course of AD dementia averages 7-10 years and culminates uniformly in death.

The first reported case of AD was described by Alois Alzheimer at the 37th Conference of South-West German Psychiatrists in Tübingen, Germany in November of 1906. There, Alzheimer described his clinicopathological evaluation of Auguste Deter, a patient who presented with a “peculiar” dementia at 51 years of age. Upon her death at age 55, Alzheimer utilized the Bielschowsky silver impregnation technique to visualize “miliary foci” and “striking changes of the neurofibrils” throughout Deter’s cerebral cortex (Alzheimer et al., 1995). These pathologies, later described as amyloid plaques
and neurofibrillary tangles, respectively, constitute the principle neuropathological hallmarks of AD.

**Amyloid-β peptide and amyloid plaque deposition**

Several decades after Alois Alzheimer’s initial description, cerebrovascular amyloid deposits and intraparenchymal extracellular amyloid plaques isolated from AD brain were discovered to be principally composed of aggregated forms of the amyloid-β (Aβ) peptide (Glenner & Wong, 1984; Masters et al., 1985). Aβ is a 38-43 amino acid peptide of unknown function that is derived from normal metabolism of amyloid precursor protein [APP; (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992)]. APP is a type I transmembrane protein that is predominantly expressed in neurons in the central nervous system and is sequentially cleaved by two proteases, β-secretase (Vassar et al., 1999) and γ-secretase (De Strooper et al., 1998), to generate Aβ. Alternative APP cleavage by the α-secretase protease occurs within the Aβ sequence and thus precludes Aβ generation (Lammich et al., 1999). Intramembranous γ-secretase cleavage of APP at various amino acid residues at the C-terminus of the Aβ sequence produces Aβ peptides of varying amino acid length and aggregation propensity. Of these, Aβ<sub>1-40</sub> is the most abundant Aβ species in the brain and cerebrospinal fluid. Present at only 5-10% of the concentration of Aβ<sub>1-40</sub>, Aβ<sub>1-42</sub> is nonetheless regarded as the primary pathogenic Aβ species as it is more hydrophobic and thus more likely to self-aggregate and seed amyloid plaque deposition (Hasegawa et al., 1999; Kim et al., 2007). Under normal conditions, Aβ is released by neurons in a soluble form and can be measured in the plasma and cerebrospinal fluid of cognitively normal individuals throughout life (Fagan et al., 2006). During AD pathogenesis, soluble Aβ aggregates into higher-order species such as soluble
oligomers and insoluble amyloid plaques in a concentration-dependent manner (Meyer-Luehmann et al., 2003). Amyloid plaque deposition in AD is associated with myriad types of neurotoxicity, including neuritic dystrophy (Brendza et al., 2005; Meyer-Luehmann et al., 2008), disrupted brain metabolism (Klunk et al., 2004; Sperling et al., 2009), decreased functional connectivity (Supekar et al., 2008; Hedden et al., 2009; Sheline et al., 2010a; Drzezga et al., 2011), neuroinflammation (Bolmont et al., 2008; Meyer-Luehmann et al., 2008), neurofibrillary tangle formation (Bolmont et al., 2007), and synaptic and neuronal loss (Jack et al., 2009).

In the years since the identification of Aβ as the primary constituent of amyloid plaques in AD brain, genetic, biochemical and neurobiological evidence has mounted to suggest that Aβ accumulation and aggregation initiate a pathogenic cascade of molecular events that ultimately culminate in symptomatic AD (Selkoe, 2000; Hardy and Selkoe, 2002). “Sporadic”, “late-onset” (age > 60 years) AD (LOAD) accounts for ~99% of symptomatic AD cases. Of the several genes in which mutations have been reported to modulate susceptibility to LOAD, the apolipoprotein E (APOE) ε4 allele confers the greatest risk and decreases average age of dementia onset by 10-20 years (Corder et al., 1993; Saunders et al., 1993). In contrast, the APOE ε2 allele confers protection and reduces risk of LOAD development (West et al., 1994). Consistent with the amyloid cascade hypothesis, CSF and amyloid imaging data suggest that cognitively normal middle-aged to elderly APOE ε4 carriers exhibit lower CSF Aβ42 levels, greater brain amyloid deposition and reduced brain glucose metabolism relative to noncarriers (Reiman et al., 1996; Sunderland et al., 2004; Reiman et al., 2009; Morris et al., 2010).
In a small percentage (~1%) of AD cases (familial AD, FAD), the disease is inherited in a fully-penetrant, autosomal dominant manner and dementia typically manifests between 30 and 60 years of age. Missense mutations in the coding sequence of APP were the first mutations identified to segregate with FAD or CAA (Levy et al., 1990; Van Broeckhoven et al., 1990; Goate et al., 1991). Since then, several mutations in APP, PSEN1 and PSEN2 have been found to result in FAD (Holtzman et al., 2011). Importantly, all identified FAD-linked mutations either increase total Aβ levels, Aβ42 levels or increase Aβ aggregation propensity (Holtzman et al., 2011).

Using positron emission tomography (PET), amyloid deposition in human brain can be directly assessed \textit{in vivo} through systemic infusion of a radiolabeled compound that readily crosses the blood-brain barrier and binds specifically to amyloid plaques (Klunk et al., 2004). Amyloid deposition in human brain can also be indirectly assessed through analysis of Aβ1-42 levels in cerebrospinal fluid (CSF); CSF Aβ1-42 concentration is significantly reduced in AD and likely reflects sequestration of soluble Aβ into parenchymal plaques (Fagan et al., 2006). Furthermore, biomarkers such as high CSF tau/Aβ42 and elevated brain amyloid deposition are predictive of conversion from cognitive normalcy to very mild dementia (Fagan et al., 2007; Morris et al., 2009; Craig-Schapiro et al., 2010) and from mild cognitive impairment to AD (Hansson et al., 2006). As cerebral amyloid plaque deposition begins 10-15 years prior to the onset of clinical symptoms (Perrin et al., 2009), preclinical detection of amyloid pathology using physiological fluid and neuroimaging biomarkers will likely represent a critical component of future AD diagnosis, treatment and prevention.

\textbf{Mouse models of Aβ plaque deposition}
Identification of mutations that result in FAD has greatly facilitated generation of AD mouse models. Though existing mouse models do not recapitulate the full complement of pathology present in human AD brain (Ashe and Zahs, 2010), they have provided valuable insights into specific components of AD pathogenesis.

Transgenic overexpression of human APP containing one or more FAD-linked mutations is sufficient to induce age-related Aβ plaque deposition in mouse brain. One such mouse model, Tg2576 (APPswe), expresses the 695 amino acid form of human APP containing the K670N/M671L FAD mutation under the transcriptional regulation of the hamster prion protein promoter (Hsiao et al., 1996). In Tg2576 mice, transgenic APP expression in neurons and astrocytes is approximately 5.5 fold greater than expression of endogenous murine APP. Parenchymal Aβ\textsubscript{1-40} and Aβ\textsubscript{1-42} levels are increased by ~5 and 14-fold, respectively (Hsiao et al., 1996; Kawarabayashi et al., 2001). Aβ plaque deposition begins between 9-10 months of age and is associated with the onset of learning and memory deficits (Hsiao et al., 1996). Importantly, Aβ plaque deposition in Tg2576 mouse brain exhibits regional specificity similar to that observed in human AD brain. Therefore, the Tg2576 mouse model represents a useful tool with which to examine the cellular and molecular mechanisms underlying brain region-specific Aβ plaque deposition.

Though mutations in PSEN1 account for the majority of FAD cases (Holtzman et al., 2011), transgenic overexpression of human PSEN1 containing FAD-linked mutations does not induce Aβ plaque deposition in mouse brain. However, coexpression of mutant human PSEN1 and APP transgenes in bitransgenic mice can hasten the onset and rate of cerebral Aβ plaque deposition relative to singly transgenic APP mutant mice (Borchelt et
al., 1997; Holcomb et al., 1998; Lamb et al., 1999; Jankowsky et al., 2004). Accordingly, Aβ plaque deposition begins between 4-5 months of age in APPswe/PS1ΔE9 (APP/PS1) bitransgenic mice. The degree of acceleration of Aβ plaque deposition is proportional to the increase in the Aβ 42:40 ratio induced by mutant PSEN1 (Jankowsky et al., 2004). Though the mechanisms are unclear, regional differences in Aβ plaque deposition are less robust in APP/PS1 compared to Tg2576 mice.

**Neuronal activity and ISF Aβ metabolism**

Following its intracellular generation, Aβ is secreted into the extracellular fluid of the brain in soluble form (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992). Given that amyloid plaques are extracellular structures, and that Aβ aggregation is concentration-dependent (Hasegawa et al., 1999; Meyer-Luehmann et al., 2003), the concentration of soluble Aβ within the brain extracellular fluid is hypothesized to represent a key determinant of whether and when Aβ will aggregate *in vivo*. Therefore, several reports have sought to elucidate the mechanisms that regulate Aβ release into the brain extracellular fluid. In 1992, two reports demonstrated that pharmacological activation of cell-surface M1 or M3 muscarinic acetylcholine receptor subtypes increased release of APP derivatives in cell culture (Buxbaum et al., 1992; Nitsch et al., 1992). In the following year, these findings were extended by the demonstration that electrical depolarization of rat hippocampal slices increased release of APP derivatives and that electrical stimulation-induced APP derivative release was prevented by the addition of tetrodotoxin, a voltage-gated sodium channel blocker (Nitsch et al., 1993). Using APP transgenic mice and rat organotypic hippocampal slices infected with human APP, Kamenetz and colleagues later showed that a pharmacological increase of neuronal
activity by picrotoxin, a GABA<sub>A</sub> receptor antagonist, increased Aβ generation and secretion while a decrease in neuronal activity by tetrodotoxin decreased Aβ generation and secretion (Kamenetz et al., 2003). However, the role of neuronal activity in Aβ formation and secretion in vivo remained unknown.

To test the hypothesis that neuronal activity directly regulates Aβ secretion into the extracellular fluid in vivo, Cirrito and colleagues in our laboratory utilized a novel Aβ microdialysis technique (Cirrito et al., 2003) to sample Aβ concentration in the brain interstitial fluid (ISF) of awake, behaving mice while performing electrical or pharmacological manipulation of neuronal activity (Cirrito et al., 2005). Consistent with findings showing that APP is axonally transported from entorhinal cortex to hippocampus via the perforant pathway (Buxbaum et al., 1998), and that perforant pathway lesions reduce hippocampal Aβ plaque deposition in APP transgenic mice (Lazarov et al., 2002; Sheng et al., 2002), Cirrito and colleagues found that acute electrical stimulation of the perforant pathway increased ISF Aβ levels in hippocampus of APP transgenic mice within minutes (Cirrito et al., 2005). Moreover, they found that hippocampal infusion of tetrodotoxin via reverse microdialysis reversibly reduced ISF Aβ and EEG amplitude and that pharmacological inhibition of synaptic vesicle exocytosis via tetanus toxin reduced ISF Aβ levels. Finally, they used organotypic hippocampal slice culture to show that stimulation of synaptic vesicle exocytosis increased ISF Aβ levels in the absence of action potentials, suggesting that synaptic activity directly regulates ISF Aβ concentration in vivo (Cirrito et al., 2005). Consistent with in vitro reports showing that cell-surface APP is internalized by clathrin-mediated endocytosis (Nordstedt et al., 1993) and that APP is cleaved by β-secretase and γ-secretase within early and late endosomes to produce
Aβ (Vassar et al., 1999; Lah and Levey, 2000), the majority (~70%) of synaptic Aβ secretion in vivo was later demonstrated to require clathrin-mediated endocytosis (Cirrito et al., 2008).

Recent reports from our laboratory have demonstrated that certain behavioral and environmental manipulations regulate ISF Aβ levels at least in part through modulation of neuronal activity. For instance, acute and chronic restraint stress increase hippocampal ISF Aβ levels in APP transgenic mice and stress-induced increases in ISF Aβ levels are prevented by local infusion of tetrodotoxin (Kang et al., 2007). Consistent with previous reports suggesting that wakefulness is associated with increased cerebral glucose utilization and synaptic potentiation compared to sleep (Vyazovskiy et al., 2008b; Vyazovskiy et al., 2008a; Gilestro et al., 2009), our laboratory has also demonstrated that hippocampal ISF Aβ levels exhibit diurnal fluctuation in both APP transgenic and wild-type mice (Kang et al., 2009). Moreover, acute sleep deprivation increases ISF Aβ levels in hippocampus while chronic sleep deprivation exacerbates Aβ plaque deposition (Kang et al., 2009). However, whether physiological neuronal activity regulates ISF Aβ levels remains unclear.

**Default-mode network and Aβ deposition**

Much of the knowledge gained from human neuroimaging comes from experiments in which a task-induced change in neural activation is measured relative to a resting-state control condition. Using this approach, one can visualize localized stimulus-induced changes in brain activation and thus relate brain topography to function (Petersen et al., 1988; Buckner et al., 1999). However, given that the resting human brain
consumes 20% of the body’s energy and that task-related increases in brain activation are minor (< 5%) relative to resting brain metabolism, most of the knowledge gained from human neuroimaging comes from examination of a small fraction of total brain activity. Indeed, an early study of cerebral energy metabolism found no significant change in global brain metabolism during performance of a challenging arithmetic problem relative to a quiet resting state (Sokoloff et al., 1955).

In cognitively normal adults, it is now well-established that a specific set of brain regions, including medial prefrontal, lateral parietal, posterior cingulate/retrosplenial cortices, is preferentially activated during undirected mentation and is deactivated during task performance. As activity in this neural network is most robust in the absence of a task, this subset of brain regions was termed the “default-mode network” (Raichle et al., 2001; Raichle and Mintun, 2006; Raichle and Snyder, 2007). Activity in the default-mode network is typically ascribed to self-referential thinking, autobiographical memory retrieval and planning for future events (Buckner et al., 2008). Importantly, as resting-state brain metabolism accounts for the majority of total brain metabolism, default-mode network activity is hypothesized to account for the majority of total brain activity.

A fundamental feature of AD is the deposition of extracellular Aβ plaques in specific brain regions. However, the mechanism by which specific brain regions are rendered vulnerable to Aβ plaque deposition in AD remains unknown. To begin to address this issue, Randy Buckner and colleagues used functional magnetic resonance imaging (fMRI) to show that the distribution of resting-state brain metabolism in cognitively normal young adults is closely associated with the topology of amyloid plaque deposition in AD (Buckner et al., 2005). This discovery was recently extended by
data suggesting that the distribution of resting-state aerobic glycolysis (defined as glucose utilization in excess of that used for oxidative phosphorylation despite sufficient oxygen to completely metabolize glucose to carbon dioxide and water) in cognitively normal adult brain is region-specific (Vaishnavi et al., 2010) and that the distribution of resting-state aerobic glycolysis in cognitively normal adults exhibits a strong spatial correlation with amyloid plaque deposition in AD (Vlassenko et al., 2010). However, despite evidence of a close spatial relationship between brain energy metabolism and Aβ deposition in human brain, the mechanisms by which specific brain regions are rendered vulnerable to Aβ plaque deposition in AD remain unknown. Given the near proportionality between neuronal energy consumption and neurotransmitter cycling in vivo (Hyder et al., 2006), and given that evidence from our laboratory and others suggests that neuronal activity directly regulates ISF Aβ levels in vitro and in vivo (Kamenetz et al., 2003; Cirrito et al., 2005; Cirrito et al., 2008), one possibility is that regional differences in resting-state neuronal activity regulate the regional specificity of Aβ plaque deposition through long-term modulation of ISF Aβ concentration.

**Functional connectivity and Aβ deposition**

In 1995, Biswal and colleagues observed that spontaneous fluctuations in the resting-state BOLD signal measured in left sensorimotor cortex of cognitively normal adults were correlated in time specifically with spontaneous fluctuations in right sensorimotor cortex (Biswal et al., 1995). Such temporal coherence of neural activity in spatially distinct brain regions, termed “functional connectivity”, is now recognized as an intrinsic component of normal brain metabolism (Fox and Raichle, 2007).
Recent large-scale resting-state functional connectivity MRI (fcMRI) and diffuse spectrum imaging data suggest that certain areas of human brain contain disproportionately high levels of functional and structural connectivity (Hagmann et al., 2008; Buckner et al., 2009). Intriguingly, several of these cortical “hubs” are located in regions of the default-mode network. Given that brain regions that comprise the default-mode network are those most susceptible to amyloid plaque deposition in AD, there exists a striking spatial correspondence between areas of elevated resting-state functional connectivity in cognitively normal brain and the pattern of amyloid plaque deposition in AD (Buckner et al., 2009). Moreover, recent reports have demonstrated that functional connectivity within the default-mode network is disrupted in AD (Supekar et al., 2008; Zhang et al., 2009), cognitively normal adults who harbor significant brain amyloid plaque deposition (Hedden et al., 2009; Drzezga et al., 2011) and in normal aging (Andrews-Hanna et al., 2007).

Examination of the relationships between functional connectivity, Aβ plaque deposition and normal aging would be greatly facilitated by the ability to measure systems-level functional connectivity in genetically and pharmacologically tractable model systems. However, given that the small size of mouse brain requires an exceptionally high signal-to-noise ratio to sufficiently resolve region-specific BOLD signal fluctuations, the relationship between functional connectivity, amyloid plaque deposition and normal aging remains unknown.
Chapter 2.

Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice
PREFACE

The work in this chapter was published in the August 26, 2009 issue of *The Journal of Neuroscience*. Adam W. Bero and Ping Yan (laboratory of Jin-Moo Lee) contributed equally to this work.
ABSTRACT

Amyloid plaques are primarily composed of extracellular aggregates of amyloid-β (Aβ) peptide and are a pathological signature of Alzheimer's disease. However, the factors that influence the dynamics of amyloid plaque formation and growth in vivo are largely unknown. Using serial intravital multiphoton microscopy through a thinned-skull cranial window in APP/PS1 transgenic mice, we found that amyloid plaques appear and grow over a period of weeks before reaching a mature size. Growth was more prominent early after initial plaque formation: plaques grew faster in 6-month-old compared with 10-month-old mice. Plaque growth rate was also size-related, as smaller plaques exhibited more rapid growth relative to larger plaques. Alterations in interstitial Aβ concentrations were associated with changes in plaque growth. Parallel studies using multiphoton microscopy and in vivo microdialysis revealed that pharmacological reduction of soluble extracellular Aβ by as little as 20–25% was associated with a dramatic decrease in plaque formation and growth. Furthermore, this small reduction in Aβ synthesis was sufficient to reduce amyloid plaque load in 6-month-old but not 10-month-old mice, suggesting that treatment early in disease pathogenesis may be more effective than later treatment. In contrast to thinned-skull windows, no significant plaque growth was observed under open-skull windows, which demonstrated extensive microglial and astrocytic activation. Together, these findings indicate that individual amyloid plaque growth in vivo occurs over a period of weeks and may be influenced by interstitial Aβ concentration as well as reactive gliosis.
INTRODUCTION

Amyloid-β (Aβ) is a 38-43 amino acid peptide that is produced in neurons by the sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-secretase and γ-secretase (Selkoe, 2001). Under normal conditions, Aβ is secreted into the extracellular space [interstitial fluid (ISF)] of the brain, where it is found in soluble form throughout life (Cirrito et al., 2003). Aggregation of Aβ into compact amyloid plaques is associated with local neuritic dystrophy (Knowles et al., 1999; D'Amore et al., 2003; Lombardo et al., 2003; Brendza et al., 2005; Garcia-Alloza et al., 2006; Meyer-Luehmann et al., 2008), neuronal and astrocytic calcium dysregulation (Busche et al., 2008; Kuchibhotla et al., 2008; Kuchibhotla et al., 2009) and disruption of cortical synaptic integration (Stern et al., 2004) and is widely considered to represent a necessary factor in Alzheimer's disease (AD) pathogenesis (Hardy and Selkoe, 2002). In vitro studies of Aβ aggregation kinetics demonstrate that Aβ monomers polymerize to form higher order aggregates in a concentration-dependent manner (Burdick et al., 1992). Although similar aggregation steps are believed to occur during plaque pathogenesis in the AD brain, the dynamics of this process in vivo are not well understood. Since amyloid deposits are primarily present in the extracellular space of the brain, the concentration of soluble Aβ in the ISF is likely a key determinant of Aβ aggregation. This hypothesis is supported by transplantation studies in which wild-type neural grafts in APP transgenic hosts developed amyloidosis, suggesting that host-derived soluble Aβ diffused through the ISF and seeded amyloid formation in the graft (Meyer-Luehmann et al., 2003). However, a direct relationship between soluble, extracellular Aβ and amyloid plaque growth dynamics in vivo has not been demonstrated.
Since β-secretase and γ-secretase activity is necessary for Aβ generation, drug discovery efforts have aimed to inhibit these enzymes to halt or reverse the progression of amyloid pathology in AD. However, γ-secretase is also required for the proteolysis of a multitude of other type 1 transmembrane proteins including Notch (De Strooper et al., 1999), ErbB4 (Ni et al., 2001) and CD44 (Lammich et al., 2002). Thus, complete inhibition of this enzyme is associated with significant mechanism-based toxicity, including atrophy of the thymus and altered intestinal cell differentiation (Wong et al., 2004). Interestingly, genetic reduction of γ-secretase activity throughout life by as little as 30% is sufficient to attenuate amyloid pathology in a mouse model of AD while limiting toxicity (Li et al., 2007). However, it is not known whether, and to what extent, transient pharmacological reduction of extracellular Aβ is associated with altered amyloid plaque growth dynamics in adult animals.

Given the overwhelming evidence that Aβ accumulation is necessary for AD pathogenesis, it is critical to understand the mechanisms that govern Aβ plaque formation and growth in vivo. To this end, we used serial in vivo multiphoton microscopy to monitor the growth of individual plaques over time and in vivo microdialysis to determine the relationship between ISF Aβ concentration and amyloid plaque growth in APPswe/PS1ΔE9 (APP/PS1) transgenic mice.
MATERIALS AND METHODS

Animals.

Male and female APPswe/PS1ΔE9 mice (Jankowsky et al., 2004; Savonenko et al., 2005); APP/PS1; The Jackson Laboratory) were aged to 6 ± 0.5 or 10 ± 0.5 months for multiphoton microscopy experiments and 3 ± 0.5 months for in vivo microdialysis experiments. All experimental protocols were approved by the Animal Studies Committee at Washington University.

Open-skull cranial window surgery.

Open-skull cranial windows were prepared on the day of the first imaging session as previously described (Bolmont et al., 2008; Meyer-Luehmann et al., 2008). Briefly, mice were anesthetized under volatile isoflurane (2% induction, 1.5% maintenance), and the skin and periosteum were removed to expose the skull. Lines forming a square (6 mm) were drilled into the skull surface using a high-speed drill (Fine Science Tools), and a pair of angled forceps was used to remove the circumscribed region of skull without damaging the dura mater. A glass coverslip (8 mm in diameter) was placed over the open-skull region and was sealed to the skull with dental cement. A 2-mm-high wall of dental cement was constructed around the coverslip to create a water-immersion chamber for subsequent imaging (supplemental Fig. 1A).

Thinned-skull cranial window surgery.

Thinned-skull cranial windows were prepared on the day of the first imaging session as previously described (Christie et al., 2001; Tsai et al., 2004). Briefly, mice were
anesthetized (as described above), and the skin and periosteum were removed to expose
the skull. A high-speed drill and microsurgical blade (Surgistar) were used to thin the
skull until the skull window was transparent and displayed flexibility. Pial vasculature
was clearly visualized through the window and served as a guide to repeatedly locate the
same sites in the brain at subsequent imaging sessions (supplemental Fig. 1B). Two
thinned-skull windows (each 0.8–1.0 mm in diameter) were prepared on each animal.

**Multiphoton microscopy.**

To examine plaque growth, individual plaques were observed longitudinally. Twenty-
four hours before each imaging session, animals were injected intraperitoneally with
methoxy-X04 (5 mg/ml in 10% DMSO, 45% propylene glycol, and 45% saline), a
fluorescent compound that crosses the blood–brain barrier and binds to amyloid plaques
(Klunk et al., 2002). The animal was anesthetized and mounted on a custom-built
stereotaxic apparatus (Brendza et al., 2005). For thinned-skull window preparations, a
small ring of molten bone wax was applied to the skull surrounding the perimeter of the
window to create a chamber for water immersion. The skull window was placed directly
under the objective lens on a two-photon microscope [LSM 510 META NLO system
(Carl Zeiss Inc.) with a Chameleon Ti: Sapphire laser (Coherent Inc.)]. To image
methoxy-X04-labeled plaques, two-photon fluorescence was generated with 750 nm
excitation, and fluorescent emission was detected in the range of 435–485 nm. A 10×
water-immersion objective [numerical aperture (NA) = 0.33, Zeiss] was used to create a
site map during initial imaging and a 40× water-immersion objective (NA = 0.75, Zeiss)
was used for detailed analysis of individual plaques. A z-stack image series was acquired
from the skull surface to a depth of ∼200 μm into cortex. Incremental z-step distance was
10 μm under the 10× objective and 5 μm under the 40× objective. At the conclusion of each imaging session, the animal was removed from the stage and the scalp was sutured. To examine plaque growth over time, the same sites for each animal were imaged on day 0 and day 7, 28, or 90. To determine whether laser intensity might impact plaque size determination, a visual field containing multiple plaques was repeatedly imaged using increasing laser power (14–20%) while detection gain and amplification parameters were held constant (supplemental Fig. 2A,B). No significant differences were found between the different laser intensities.

**Image analysis.**

Collapsed z-stack images for each individual plaque were measured by cross-sectional area and intensity using SigmaScan Pro Image Analysis Software (Systat Software) with a preset threshold (threshold = mean + 4 * SD) (supplemental Fig. 2C,D). Plaques were excluded from analysis if they were located on the edge of the thinned-skull window, if they exhibited a fluorescence intensity less than the mean intensity of an adjacent background region, or if the images were affected by motion artifacts (from heartbeat or respiration).

**Double immunofluorescence.**

To compare microglial and astrocytic activation in cortex under open- and thinned-skull window preparations, animals were transcardially perfused with 0.9% saline followed by 4% paraformaldehyde in 0.01 M PBS immediately after the second multiphoton imaging session. Brains were removed and postfixed in 4% paraformaldehyde for an additional 4 h. Coronal free-floating sections (50 μm) were cut on a cryostat. Sections were incubated
overnight at 4°C in a combination of rabbit anti-Iba1 (1:1000; Wako Chemicals) and mouse anti-GFAP monoclonal antibody (1:1000; Sigma). A secondary antibody mixture of Cy3-conjugated donkey anti-rabbit IgG (1:800; Jackson ImmunoResearch Laboratories) and Alexa Fluor 488-conjugated donkey anti-mouse IgG (1:400; Invitrogen) was applied. Sections were washed, mounted, and examined using a confocal microscope (Zeiss LSM).

**Compound E treatment.**

To examine the effect of reduced Aβ concentration on plaque growth dynamics, mice were treated with either vehicle or the potent γ-secretase inhibitor, Compound E (3 mg/kg; Axxora) daily for 7 or 28 d (Grimwood et al., 2005). To examine the effect of Compound E on ISF Aβ levels, mice were treated with either a single dose of 3 mg/kg Compound E (i.p.) or treated daily with vehicle or 3 mg/kg Compound E for 7 d.

**Amyloid plaque load quantification.**

To determine the effect of Compound E treatment on overall cortical amyloid plaque load, 6- and 10-month-old animals were treated with vehicle or Compound E (3 mg/kg, i.p.) daily for 28 d. Mice were subsequently transcardially perfused with 0.9% saline followed by 4% paraformaldehyde in 0.01 M PBS. Brains were dissected, fixed with 4% paraformaldehyde, cryosectioned (50-μm-thick slices), and stained with 100 μM X-34 in staining buffer (40% ethanol/60% PBS, pH 10) for 20 min and differentiated with staining buffer three times, each, for 2 min to visualize compact plaques (Styren et al., 2000). Cortical plaque load was expressed as percentage of cortical area covered by X-34-positive staining.
**In vivo microdialysis.**

*In vivo* microdialysis used to measure Aβ in the brain ISF of awake, freely behaving mice was performed as previously described (Cirrito et al., 2003; Cirrito et al., 2005; Kang et al., 2007; Cirrito et al., 2008). One day before drug treatment, guide cannulae (BR-style, Bioanalytical Systems) were stereotaxically implanted into the left barrel cortex (at bregma, 2.0 mm lateral to midline, and 1.0 mm below the dura mater at a 32° angle) of APP/PS1 mice under isoflurane volatile anesthesia. After guide cannula implantation, a 2 mm microdialysis probe [BR-2, 38 kDa MWCO (molecular weight cutoff membrane), Bioanalytical Systems] was inserted through the guide cannula so the microdialysis membrane was contained entirely within the barrel cortex. Mice were allowed to recover from anesthesia and were housed in a Raturn Cage system (Bioanalytical Systems) with *ad libitum* access to food and water for the remainder of the experiment. The microdialysis probe was connected to a syringe pump (Stoelting Co.) and artificial CSF (aCSF), containing (in mM) 1.3 CaCl$_2$, 1.2 MgSO$_4$, 3 KCl, 0.4 KH$_2$PO$_4$, 25 NaHCO$_3$, and 122 NaCl, pH 7.35, was continuously perfused through the microdialysis probe at a constant flow rate of 0.7 μl/min. Artificial CSF contained 0.15% bovine serum albumin to limit nonspecific loss of Aβ. Dialysis samples were collected using a refrigerated fraction collector (SciPro Inc.) into polypropylene tubes for subsequent measurements of Aβ$_{1-40}$, Aβ$_{x-40}$, or Aβ$_{x-42}$ by ELISA, as described below. Mice were treated intraperitoneally with either a single dose of Compound E (3 mg/kg) or daily with vehicle or Compound E (3 mg/kg) for 7 d. In single-dose experiments, baseline levels of ISF Aβ were defined as the mean concentration of Aβ 8 h before drug treatment. Because artifactual fluctuations in ISF Aβ levels are occasionally observed 3–4 d after insertion of
the microdialysis probe (our unpublished observations), we chose to monitor ISF Aβ levels during days 5, 6, and 7 of treatment in multiple-dose experiments. Based on our finding that ISF Aβ levels collected 16–24 h after a single dose of Compound E did not differ from pretreatment baseline levels, baseline levels of ISF Aβ in multiple-dose experiments were defined as the mean concentration of Aβ from hours 16–24 after each injection of Compound E. After each experiment, animals were killed.

**Aβ ELISA assay.**

Microdialysis samples were analyzed for Aβ₁₋₄₀, Aβ₂₋₄₀, or Aβ₃₋₄₂ using species-specific sandwich ELISAs. Briefly, Aβ₁₋₄₀, Aβ₂₋₄₀, and Aβ₃₋₄₂ were captured using monoclonal antibodies targeted against amino acids 13-28 (m266), 35-40 (HJ2), or 33-42 (21F12) of Aβ, respectively. The antibodies m266, 21F12, and 3D6 were gifts from Eli Lilly. For Aβ₁₋₄₀ assays, a biotinylated N-terminal domain monoclonal antibody (3D6B) followed by streptavidin-poly-HRP-20 was used to detect (Fitzgerald). For Aβ₂₋₄₀ and Aβ₃₋₄₂ assays, a biotinylated central domain monoclonal antibody (HJ5.1B) followed by streptavidin-poly-HRP-40 was used to detect (Fitzgerald). All assays were developed using Super Slow ELISA TMB (Sigma) and read on a Bio-Tek FL-600 plate reader at 650 nm.

**Statistical analysis.**

Longitudinal changes in cross-sectional area of individual plaques were analyzed using paired *t* tests. Differences in average fold increase of amyloid plaques at multiple time points as a function of imaging interval were analyzed using a one-way ANOVA followed by Dunn's *post hoc* test. To assess differences in individual plaque growth as a function of drug treatment, the fold increase of mean plaque size was analyzed using a
paired $t$ test (SigmaStat statistical software v 2.0, Systat Software). Group differences in percentage area covered by X-34-positive staining were analyzed by Student's $t$ tests. In microdialysis experiments, time point comparisons of ISF Aβ levels were performed using one- and two-way ANOVAs followed by Bonferroni post hoc $t$ tests. Differences in mean ISF Aβ levels between groups were compared using a paired $t$ test (GraphPad Prism v 4.0). All data in figures represent mean ± SEM. In all tests, the level of significance was set at $p \leq 0.05$. 
RESULTS

Amyloid plaques exhibit age- and size-related growth under thinned-skull windows

Using serial intravitral multiphoton microscopy, individual amyloid plaques were imaged through thinned-skull cranial windows over 7, 28, and 90 d intervals in 6- and 10-month-old APP/PS1 transgenic mice. In 6-month-old mice, plaque size increased significantly over 7, 28, and 90 d intervals (Figs. 1, 2A–C; supplemental Fig. 4A,C). Over a 7 d interval, 21% of plaques grew by at least twofold, with a maximum of fourfold growth (Fig. 2A; supplemental Fig. 4A). Over a 28 d interval, 62% of plaques increased by twofold or more, with a maximum of sixfold growth (Fig. 2B; supplemental Fig. 4A,C). Notably, the average fold increase in plaque size over a 90 d period was no greater than that observed over the 28 d period, suggesting that plaques adopted a stable size before these two imaging time points (Fig. 2C,D; supplemental Fig. 4A). Although the net effect of plaque dynamics indicated average plaque growth, there was a great deal of variability. Indeed, many plaques remained stable during the observed time intervals and rare examples of plaque regression were also evident (supplemental Fig. 4B). In contrast to plaque growth observed in 6-month-old animals, plaques imaged in 10-month-old mice did not exhibit significant growth over 7 or 90 d periods (Fig. 2D). Plaque growth was also related to plaque size, as smaller plaques exhibited a greater growth rate compared with larger plaques regardless of animal age (Fig. 2E). Consistent with these findings, plaques sampled in 6-month-old mice exhibited a smaller mean size than 10-month-old mice and showed greater mean growth (supplemental Fig. 3C). Moreover, newly formed plaques were significantly smaller than preexisting plaques (supplemental Fig. 3D). Thus, individual amyloid plaque growth in vivo is related to animal age and plaque size.
Open-skull cranial window preparations do not show plaque growth and are associated with extensive gliosis

In contrast to the robust plaque growth observed under thinned-skull window preparations, plaques imaged in 6-month-old APP/PS1 mice under open-skull cranial window preparations did not exhibit significant growth but did show some evidence of regression over a 28 d interval (Fig. 2F; supplemental Fig. 4C). These findings are consistent with two recent two-photon studies using open-skull windows (Bolmont et al., 2008; Meyer-Luehmann et al., 2008). Technical differences between the two window types are shown in supplemental Figure 1, and include open (craniotomy)- versus closed-skull preparations, size differences (6 mm diameter in open-skull vs <0.8 mm in closed-skull windows), and the presence of a foreign body (coverslip) in open-skull windows versus none in closed-skull windows. To examine functional consequences of the different cranial window types, we performed a comparative analysis of microglial and astrocytic activation under thinned- and open-skull window preparations. Seven days after open-skull surgery, extensive microglial activation (Iba-1 immunostain, Fig. 3A) was present in cortex under the open-skull window, whereas activated microglia were largely absent in the contralateral control hemisphere. Astrocytic activation (GFAP immunostain, Fig. 3B) was also abundant in cortex under the open-skull window but rare in contralateral control cortex. Even at low power, extensive immunostaining is visible in the region immediately below the cranial window. In contrast, microglial and astrocytic activation occurred only immediately surrounding plaques under thinned-skull window preparations and was indistinguishable from the respective contralateral control hemispheres (Fig. 3C,D). These results indicate that open-skull, but not thinned-skull,
window preparations are associated with extensive cortical gliosis and suggest that reactive glial activation may underlie the suppressed plaque growth dynamics observed under open-skull window preparations. Our findings are consistent with those of Dr. W. G. Bao, who has reported increased gliosis under open-skull windows associated with altered dynamics in synaptic spine behavior (Xu et al., 2007). Thus, for the remaining multiphoton studies, all experiments were performed using thinned-skull windows.

**γ-Secretase inhibition suppresses plaque growth and new plaque appearance in vivo**

To assess the effects of reduced Aβ production on longitudinal growth of individual plaques, we measured plaque growth in 6- and 10-month-old APP/PS1 mice treated with either the potent γ-secretase inhibitor, Compound E (3 mg/kg), or vehicle daily for 7 or 28 d ($n = 4$/group). Compound E suppressed plaque growth in 6-month-old mice over 7 and 28 d intervals (Fig. 4). Treatment for 28 d in 6-month-old animals also dramatically attenuated the appearance of new plaques: $0.4390 \pm 0.1391$ new plaques per mm$^3$ in vehicle-treated versus $0.0506 \pm 0.039$ in Compound E-treated mice (Student's $t$ test, $*p \leq 0.05$). In contrast, plaques imaged in 10-month-old mice did not exhibit significant growth over the 7 or 90 d interval regardless of drug treatment (supplemental Fig. 5). Importantly, although Compound E treatment was sufficient to dramatically decrease plaque growth, it did not induce regression in average plaque size.

To determine whether suppressed growth of individual plaques was reflective of changes in overall plaque burden, 6- and 10-month-old APP/PS1 mice were treated with Compound E (3 mg/kg) or vehicle daily for 28 d ($n = 8$/group); mice were killed, brains were sectioned and immunostained, and compact plaque load was determined.
Compound E reduced X-34-positive cortical plaque burden by 23% in 6-month-old mice compared with vehicle-treated controls (Fig. 5). No difference was detected in 10-month-old mice, similar to findings recently reported (Garcia-Alloza et al., 2009). These results indicate that modest γ-secretase inhibition was sufficient to decrease amyloid plaque load and size when administered during the plaque growth phase and suggest that longitudinal growth of individual amyloid plaques is a fundamental mechanism by which plaque load increases in AD. Of note, individual plaque growth measured by multiphoton microscopy ($n = 4$) is a much more sensitive measure than average grouped plaque burden measures ($n = 8$).

**Modest reduction in ISF Aβ concentration is associated with a dramatic reduction in amyloid plaque growth in vivo**

We next performed in vivo microdialysis experiments to determine the extent to which this dose of Compound E affects ISF Aβ concentrations. Three-month-old APP/PS1 mice were treated with a single dose of Compound E (3 mg/kg) while cortical in vivo microdialysis was performed to directly measure ISF Aβ levels in living mice. Compound E treatment decreased ISF $\text{Aβ}_{1-x}$ by 27% during the first 8 h after treatment and had no effect during the remaining 16 h of sample collection ($n = 6$; supplemental Fig. 6A,B). To determine the effect of 7 d treatment with Compound E on ISF Aβ, we treated 3-month-old APP/PS1 mice with Compound E (3 mg/kg) or vehicle for 7 d and performed microdialysis during the final 3 d of drug treatment. Compound E treatment decreased ISF $\text{Aβ}_{x-40}$ and $\text{Aβ}_{x-42}$ levels by 41% ($n = 4$/group) and 44% ($n = 4$/group), respectively, during the first 8 h after injection compared with controls (Fig. 6A,B). $\text{Aβ}_{x-40}$ and $\text{Aβ}_{x-42}$ levels exhibited more modest reductions during hours 8–16 after Compound E
treatment and were no different from controls during the final 8 h after injection (Fig. 6A,B). Expressed as relative levels over a 24 h period, Compound E reduced ISF Aβx-40 levels by 22% (n = 4/group) and Aβx-42 by 25% (n = 4/group) compared with controls (Fig. 6C). Together, these results suggest that a modest decrease in ISF Aβ levels may be sufficient to arrest amyloid plaque growth in vivo.
DISCUSSION

Amyloid plaques, primarily composed of aggregated Aβ, exist in the extracellular space of the brain and are a pathological hallmark of AD. However, the factors that govern the formation and growth of plaques in the living brain are unknown. In the present study, we used serial in vivo multiphoton microscopy in APP/PS1 mice to directly quantify amyloid plaque formation and growth in vivo. We found that although many plaques remained stable in size at both ages examined, plaques imaged in 6-month-old APP/PS1 mice exhibited robust growth relative to plaques found in 10-month-old mice, suggesting that plaque growth is more prominent early in disease pathogenesis. This finding is consistent with reports of biphasic development of plaque load in APP transgenic mice; compact plaque load is reported to increase with age (Sturchler-Pierrat et al., 1997; Wengenack et al., 2000; Jack et al., 2005; Braakman et al., 2006; Harigaya et al., 2006) before stabilizing at later disease stages (Gordon et al., 2002). Plaque load stabilization has also been hypothesized to occur in human AD patients, as amyloid burden does not correlate with disease duration (Hyman et al., 1993; Engler et al., 2006) and plaque burden in a subset of patients with mild cognitive impairment is indistinguishable from AD patients (Lopresti et al., 2005; Price et al., 2005; Mintun et al., 2006). Our study also indicated that plaque growth was related to plaque size, as smaller plaques exhibited greater rates of growth compared with larger plaques, regardless of age.

We also found that treatment with the γ-secretase inhibitor, Compound E, markedly decreased the appearance of new plaques and growth of preexisting plaques in APP/PS1 mice. This suppression in plaque appearance and growth was reflected in a decrease in total plaque burden in parallel cross-sectional studies. To determine the extent to which
Compound E treatment reduced soluble extracellular Aβ levels *in vivo*, we used *in vivo* microdialysis to measure ISF Aβ levels in APP/PS1 mice treated with Compound E. Chronic dosing of Compound E over a 7 d period decreased ISF Aβ$_{40}$ and Aβ$_{42}$ levels by only 20–25% over a 24 h period. That reduced extracellular Aβ concentration is associated with inhibition of amyloid plaque growth but not plaque regression is consistent with previous data obtained using transgenic mice that overexpress mutant APP under the regulation of a tetracycline-responsive promoter. Inhibition of mutant APP expression for 6 months after plaque formation arrested the progression of amyloid pathology but did not reduce overall plaque burden (Jankowsky et al., 2005). A more recent report demonstrated that 3 weeks of treatment with an orally active γ-secretase inhibitor did not reduce size of existing plaques in APP/PS1 mice (Garcia-Alloza et al., 2009). Together, these studies suggest that a kinetic disequilibrium between Aβ plaque aggregation and dissociation may exist *in vivo*.

The hypothesis that soluble extracellular Aβ concentration is a key determinant of Aβ aggregation *in vivo* is supported by data demonstrating that areas of the brain that ultimately develop plaque pathology have higher basal ISF Aβ levels early in life relative to brain regions that do not develop pathology (Cirrito et al., 2003). Moreover, intracerebral injection of Aβ-containing brain extract from human AD patients or APP transgenic mice induces cerebral amyloidosis in APP transgenic mice in a concentration-dependent manner (Meyer-Luehmann et al., 2003). Although correlative, the present study is the first demonstration of the relationship between soluble ISF Aβ and amyloid plaque growth *in vivo*. Moreover, it is the first report that this relationship can be modulated with pharmacological intervention. That a modest reduction of ISF Aβ levels
is associated with inhibition of amyloid plaque growth and attenuation of new plaque formation is consistent with recent data demonstrating that a 30% reduction in γ-secretase activity, as seen with knocking out γ-secretase components throughout life, can attenuate plaque burden in a mouse model of AD (Li et al., 2007). Thus, partial γ-secretase inhibition may be sufficient to arrest amyloid plaque progression in AD.

A number of potential therapeutic implications follow from the results of the present study. First, the observation that γ-secretase inhibition can prevent growth of existing plaques and attenuate new plaque formation, but not induce plaque regression suggests that anti-Ab treatments may be most efficacious if administered early in disease pathogenesis. This hypothesis is supported by our cross-sectional study, showing that 28 d Compound E treatment reduced amyloid plaque load in 6-month-old APP/PS1 mice, but not in 10-month-old mice. Moreover, our finding that a modest reduction in soluble, extracellular Ab is associated with a dramatic reduction in plaque growth and formation may have important implications for drug dosing and pharmacodynamic effects of anti-Ab therapeutics to be used in clinical trials.

Our present observations of individual plaque growth over a period of weeks are in contrast to a recent report which showed that plaques reach a mature size within 24 h after appearance (Meyer-Luehmann et al., 2008). We hypothesized that these differences might be due to different techniques used to create transcranial windows. We used a small (<0.8 mm diameter) closed thinned-skull window in our experiments, in contrast to the larger (6 mm diameter) open-skull (craniotomy) window used by Meyer-Luehmann et al. (2008) (see supplemental Fig. 1A,B). A direct comparison of plaque growth using these two techniques revealed robust growth under thinned-skull window preparations,
but no significant growth under open-skull preparations. In addition, the open-skull preparation was associated with extensive cortical microglial and astrocytic activation, which was largely absent under the thinned-skull window. These findings are consistent with a previous comparison of these two techniques, which demonstrated that the open-skull window resulted in significant reactive gliosis and an alteration of dendritic spine dynamics compared with the closed thinned-skull window (Xu et al., 2007). Coupled with previous reports implicating reactive gliosis in plaque size maintenance and regression (Gordon et al., 2002; Wyss-Coray et al., 2003; El Khoury et al., 2007; Takata et al., 2007; Bolmont et al., 2008), this may explain the discrepancy between the findings using the two different techniques.

In summary, our results suggest that individual amyloid plaques grow over a period of weeks and that the rate of plaque growth is related to disease stage, plaque size, gliosis, and soluble extracellular Aβ concentration. Thus, growth of individual plaques may be a fundamental mechanism by which plaque load increases in AD. Furthermore, the present results suggest that a decrease in ISF Aβ levels by as little as 20–25% at key time points in plaque development may be sufficient to prevent the progression of amyloid pathology.
Figure 1. Serial in vivo multiphoton microscopy demonstrates growth of individual amyloid plaques. (A, B) Epifluorescence micrographs of 4 plaques labeled with methoxy-X04 and imaged over a 7-day interval in the brain of a 6 month-old APP/PS1 mouse. (C, D) Multiphoton micrographs of those same 4 plaques illustrate growth of individual plaques over time. Scale bars: 20μm.
Figure 2. Amyloid plaques exhibit age- and size-related growth under thinned-skull window preparations. Using serial intravital multiphoton microscopy, individual plaques were labeled with methoxy-X04 and imaged at multiple time points. Plaque growth was expressed as fold-increase in cross-sectional area relative to initial plaque size. (A-C) In 6 month-old APP/PS1 mice, plaques exhibited significant growth over 7-, 28- and 90-day intervals (Paired t-test, *=p≤0.05). (D) Time course of plaque growth in 6 and 10 month-old mice. In 6 month-old animals, the average fold-increase in plaque size over a 28-day period was significantly greater than that observed over a 7-day period. There was no difference between average fold-increase over a 28-day period compared to that over a 90-day period (one-way ANOVA followed by Dunn’s post-hoc test, *=p≤0.05). Plaques imaged in 10 month-old animals did not exhibit significant plaque growth at either the 7- or 90-day interval (Paired t-test). (E) Average plaque growth is plotted as a function of initial plaque size. Regardless of animal age, smaller plaques
grew at a greater rate compared to larger plaques. (F) Plaques imaged in 6 month-old animals under open-skull window preparations did not exhibit significant growth over a 28-day interval.
Figure 3. **Open-skull cranial window preparations are associated with extensive gliosis.** *A* Low-magnification image of Iba-1 immunofluorescence (red) illustrates extensive microglial activation in cortex under the open-skull cranial window but not in contralateral control cortex. High-power micrographs colabeled for methoxy-X04-positive plaques (blue) reveal little microglial activation in control hemisphere (*A1*), but robust microglial activation under the open-skull window (*A2*). *B* Low magnification image of GFAP immunofluorescence (green) demonstrates extensive activation of astrocytes in cortex under the open-skull cranial window. High-power micrographs illustrate astrocytic activation only in the immediate vicinity of plaques in control cortex.
(B1), while robust astrocytic activation is present throughout cortex under the open-skull window (B2). (C) Iba-1-positive microglia are not abundantly visible at low-magnification under a thinned-skull cranial window preparation. High-power micrographs illustrate rare microglial activation in control cortex (C1) and under the thinned-skull window (C2). (D) Astrocytic activation is not robust at low-magnification under a thinned-skull window preparation. Astrocytic activation is rare in control cortex (D1) and under the thinned-skull window (D2). Scale bars: A-D, 200 μm; A1-D2, 50 μm.
Figure 4. γ-secretase inhibition suppresses plaque growth and new plaque formation. (A, B) Representative multiphoton micrographs of plaques imaged at a 28-day interval in a vehicle-treated 6 month-old APP/PS1 mouse illustrate growth of existing plaques (arrows) and appearance of new plaques (arrow heads). (C, D) Plaque growth was suppressed in mice treated with the γ-secretase inhibitor, Compound E (3 mg/kg, i.p). All images are collapsed z-stack images (100-120 μm thick). (E) Plaques imaged in vehicle-treated mice exhibited significant growth over 7- and 28-day intervals, while
plaque growth was attenuated in Compound E-treated mice. \((n=4 \text{ mice/group}; \text{Student's t-test, } *p \leq 0.05)\). The dotted line indicates no growth, and scale bars = 20 μm.
Figure 5. γ-secretase inhibition reduces plaque load in 6 month-old APP/PS1 mice.

Six and 10 month-old APP/PS1 mice were treated daily with Compound E (3 mg/kg, i.p.) or vehicle for 28 days. Compound E reduced X-34-positive cortical plaque load by 23% in 6 month-old animals compared to vehicle-treated controls. No difference was present between groups in 10 month-old animals (n=8 mice/group; Student's t-test, *p≤0.05).
Figure 6. γ-secretase inhibition results in modest decreases in ISF Aβ levels in cortex. Three month-old APP/PS1 mice were treated daily with Compound E (3 mg/kg, i.p.) or vehicle for 7 days. In vivo microdialysis was performed to measure ISF Aβ₄₀ and Aβ₄² in cortex throughout the final 3 days of drug treatment. (A, B) Compound E reduced ISF Aβ₄₀ and Aβ₄² levels by 42% and 44%, respectively, during the first 8 hours after each treatment compared to vehicle-treated controls. ISF Aβ₄₀ and Aβ₄² exhibited more modest decreases during hours 8-16 after Compound E treatment and were no different from controls during hours 16-24 (n=4/group, two-way ANOVA with post-hoc Bonferroni tests; *=p≤0.05). (C) Expressed as relative levels over 24 hours,
mice treated with Compound E for 7 days exhibited a 22% decrease in ISF Aβ₄₀ and a 25% decrease in Aβ₄₂ compared to controls (n=4/group; Paired t-test; *= p≤0.05).
Supplemental figure 1. Schematic representation of open- and thinned-skull cranial window preparations. (A) In open-skull cranial window preparations, a craniotomy is performed to remove a large (6 mm diameter) section of skull. A glass coverslip is placed over the resultant window and acrylic is used to cement the coverslip in place. (B) In thinned-skull cranial window preparations, a small (< 0.8 mm diameter) section of skull is thinned using a high-speed drill and microknife until transparent. (Insets) In each preparation, the pial vasculature is clearly visible through the cranial window and serves as a guide to facilitate locating the same plaque over multiple imaging sessions.
Supplemental figure 2. Laser power does not affect plaque size determination. (A)

Several high power fields containing multiple plaques were repeatedly imaged using increasing laser power (14-20%) while detection gain and amplification parameters were
held constant. No significant differences in plaque size determination were present across laser intensities. (B) Representative micrographs illustrate no difference in average plaque size as a function of laser power. (C, D). A pre-set threshold (threshold = mean + 4*(standard deviation); Sigmascan Pro Image Analysis software) was used to capture methoxy-X04-labeled plaques while excluding background staining in all cross-sectional area calculations.
Supplemental figure 3. Ten month-old APP/PS1 mice do not exhibit significant average plaque growth. (A) Average plaque growth was not significant at 7-day or (B) 90-day intervals in 10 month-old APP/PS1 mice. (C) Average absolute plaque size sampled in 6 month-old mice appeared smaller than that in 10 month-old mice and plaques imaged in 6 month-old mice showed greater mean growth than those imaged in 10 month-old mice. (D) Newly formed plaques are significantly smaller than pre-existing plaques in 6 month-old animals imaged at a 28-day interval (n=4 mice/group; Student’s t-test, *=p≤0.05).
Supplemental figure 4. Frequency distribution plots indicate that plaque growth dynamics are related to animal age and skull window preparation. (A) Plaques imaged under thinned-skull window preparations in 6 month-old APP/PS1 mice exhibited modest growth over 7-day intervals and more robust growth over 28- and 90-day intervals. (B) Plaque growth was less pronounced under thinned-skull preparations in 10 month-old mice. (C) Comparative analysis of plaque growth over a 28-day interval under thinned- vs. open-skull window preparations in 6 month-old mice suggested that plaques imaged under thinned-skull windows exhibited robust growth with little evidence of regression. In contrast, plaques imaged under open-skull windows did not exhibit significant growth but showed a greater frequency of regression.
Supplemental figure 5. γ-secretase inhibition does not alter plaque growth in 10 month-old APP/PS1 mice. Ten month-old APP/PS1 mice were treated daily with vehicle or Compound E (3 mg/kg, i.p.) for 7 days (n=4 mice/group). Plaque growth is expressed as a percentage of cross-sectional area at the initial imaging session. No significant difference in average plaque size was present between groups.
Supplemental figure 6. Compound E transiently reduces ISF Aβ concentration.

Three month-old APP/PS1 mice were treated with a single dose of Compound E (3 mg/kg, i.p.) while cortical *in vivo* microdialysis was performed to continuously measure ISF Aβ levels in living mice. (*A, B*) Compound E treatment decreased ISF Aβ₁₋₅ by 27% during the first 8 hours after treatment and had no effect during the remaining 16 hours of sample collection (*n*=6).
Chapter 3.

Neuronal activity regulates the regional vulnerability to amyloid-β deposition
PREFACE

The work in this chapter was published in the June 2011 issue of *Nature Neuroscience*.

The majority of the work was performed by Adam W. Bero with technical assistance from Ping Yan (laboratory of Jin-Moo Lee), Jee Hoon Roh, Floy Stewart and John R. Cirrito (laboratory of John R. Cirrito).
ABSTRACT

Amyloid-β (Aβ) plaque deposition in specific brain regions is a pathological hallmark of Alzheimer's disease. However, the mechanism underlying the regional vulnerability to Aβ deposition in Alzheimer's disease is unknown. Herein, we provide evidence that endogenous neuronal activity regulates the regional concentration of interstitial fluid (ISF) Aβ, which drives local Aβ aggregation. Using in vivo microdialysis, we show that ISF Aβ concentrations in several brain regions of APP transgenic mice before plaque deposition were commensurate with the degree of subsequent plaque deposition and with the concentration of lactate, a marker of neuronal activity. Furthermore, unilateral vibrissal stimulation increased ISF Aβ, and unilateral vibrissal deprivation decreased ISF Aβ and lactate, in contralateral barrel cortex. Long-term unilateral vibrissal deprivation decreased amyloid plaque formation and growth. Our results suggest a mechanism to account for the vulnerability of specific brain regions to Aβ deposition in Alzheimer's disease.
INTRODUCTION

Alzheimer's disease is the most common type of dementia and is characterized by insidious degeneration of brain systems that subserve memory and cognition. Accumulation and aggregation of the Aβ peptide in the extracellular space of the brain is a pathological hallmark of Alzheimer's disease. Aβ is produced in neurons by sequential proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretase (Selkoe, 2001). Under normal conditions, Aβ is secreted into the interstitial fluid (ISF) of the brain, where it is present in a soluble form throughout life (Cirrito et al., 2003). In Alzheimer's disease pathogenesis, Aβ aggregates into higher-order species such as soluble oligomers and insoluble amyloid plaques in a concentration-dependent manner. As amyloid plaques are extracellular structures, the concentration of Aβ in the ISF is likely to be a key determinant of whether and when Aβ will aggregate (Meyer-Luehmann et al., 2003). Consistent with this hypothesis, we have recently shown that ISF Aβ concentration is closely associated with amyloid plaque growth and formation in vivo (Yan et al., 2009).

In Alzheimer's disease–affected brain, amyloid plaque deposition is most prominent in the 'default-mode network'—a network of brain regions that shows elevated metabolic activity and aerobic glycolysis during undirected mentation (Raichle et al., 2001; Buckner et al., 2005; Buckner et al., 2008; Buckner et al., 2009; Vaishnavi et al., 2010; Vlassenko et al., 2010). Indeed, default network dysfunction is present in Alzheimer's disease patients (Greicius et al., 2004) as well as cognitively normal adults who harbor appreciable amyloid burden (Hedden et al., 2009; Sperling et al., 2009). However, the mechanism underlying the vulnerability of specific brain regions to amyloid deposition in
Alzheimer's disease is not known. Given the near direct proportionality between neuronal energy consumption and neurotransmitter cycling \textit{in vivo} (Hyder et al., 2006), this correspondence raises the possibility of a relationship between patterns of neuronal activity throughout life and the topography of amyloid deposition in Alzheimer's disease. Evidence from our laboratory and others suggests that synaptic activity regulates Aβ production and secretion into the ISF \textit{in vitro} (Kamenetz et al., 2003; Wei et al., 2010) and \textit{in vivo} (Cirrito et al., 2005; Cirrito et al., 2008). For example, electrical stimulation of the perforant pathway increases ISF Aβ in hippocampus, whereas blockade of synaptic vesicle exocytosis decreases ISF Aβ. However, the relationship between endogenous regional differences in neuronal activity and amyloid deposition remains unknown. Herein, we provide data suggesting that regional differences in endogenous neuronal activity dynamically regulate Aβ levels and have implications for the development of Aβ-related pathology.
MATERIALS AND METHODS

Mice.

Male and female Tg2576+/− (Hsiao et al., 1996) × B6SJL mice (Taconic Farms) were used at 17.5 ± 0.5 months of age for Aβ immunohistochemistry and X-34 staining experiments and 3.5 ± 0.5 months of age for all other experiments. Male and female wild-type (B6SJL) mice were used at 5.5 ± 0.5 months of age. Male and female APPswe; PSEN1ΔE9 (Jankowsky et al., 2004) × B6C3 (APP/PS1; The Jackson Laboratory) were used at 7–7.5 months of age. When two or more groups of mice were compared, groups were sex-matched. Mice were given ad libitum access to food and water. All experimental protocols were approved by the Animal Studies Committee at Washington University.

Plaque deposition analyses.

Brain tissue was dissected and flash-frozen for 1 min in isopentane chilled with dry ice before sectioning on a cryostat (Leica). Serial coronal sections (30-μm section thickness) were collected from the genu of the corpus callosum to caudal hippocampus. Sections (each separated by 180 μm) were stained with biotinylated 3D6 antibody (anti-Aβ1-5; generous gift from Eli Lilly) to visualize Aβ immunopositive plaques or X-34 dye to visualize fibrillar amyloid plaques. Immunostained sections were scanned using a NanoZoomer slide scanner (Hamamatsu Photonics). X-34–stained sections were imaged using a fluorescence microscope (Nikon) and images were captured using a digital CCD color camera (QCapture Pro version 6.0, QImaging). Quantitative analysis of percentage area covered by immuno- or X-34–positive staining was performed as described
previously (Kim et al., 2009b). Briefly, images of immunostained sections were exported with NDP viewer software (Hamamatsu Photonics), converted to 8-bit grayscale using ACDSee Pro 2 software (ACD Systems), thresholded to highlight Aβ-specific staining and analyzed using ImageJ software (National Institutes of Health). Images of X-34–stained sections were converted to 16-bit grayscale, thresholded to highlight X-34–specific staining and analyzed using ImageJ software. A mouse brain atlas (Franklin and Paxinos, 1996) was used to identify piriform cortex, cingulate cortex, barrel cortex, hippocampus and striatum for quantitative analysis of immuno- and X-34–positive staining.

**In vivo microdialysis.**

*In vivo* microdialysis used to measure Aβ in the brain ISF of awake, freely behaving mice was performed essentially as described (Cirrito et al., 2003). Briefly, guide cannulae (BR-style, Bioanalytical Systems) were stereotaxically implanted into piriform cortex (bregma + 1.0 mm, 3.8 mm lateral to midline, 1.2 mm below the dura at a 21° angle), barrel cortex (at bregma, 2.0 mm lateral to midline, 1.0 mm below the dura at a 32° angle), hippocampus (bregma − 3.1 mm, 2.5 mm lateral to midline, 1.2 mm below the dura at a 12° angle) or striatum (bregma + 0.5 mm, 1.8 mm lateral to midline, 1.4 mm below the dura at a 0° angle) for measurement of steady-state Aβ and lactate. For vibrissal trimming and stimulation experiments, guide cannulae were implanted into posterior barrel cortex (bregma − 1.5 mm, 1.7 mm lateral to midline, 0.7 mm below the dura at a 49° angle). Probe placement in the region of interest was verified by cresyl violet staining. Microdialysis probes (2 mm; 38 kDa molecular weight cut-off; BR-style, BioAnalytical Systems) were connected to a syringe pump (Stoelting) and artificial cerebrospinal fluid,
pH 7.35, containing (in mM) 1.3 CaCl₂, 1.2 MgSO₄, 3 KCl, 0.4 KH₂PO₄, 25 NaHCO₃, and 122 NaCl was continuously perfused through the microdialysis probe at a constant flow rate. For measurement of Aβ₄₀, Aβ₄₂ and lactate in Tg2576 mice, a flow rate of 1.0 μl min⁻¹ was used. For measurement of Aβ₄₂ in Tg2576 mice, a flow rate of 0.3 μl min⁻¹ was used. For measurement of Aβ₄₀ and lactate in wild-type (B6SJL) mice, a flow rate of 0.5 μl min⁻¹ was used. For PTX and TTX infusion by means of reverse microdialysis into hippocampi of young Tg2576 mice, a stable baseline of ISF Aβ₄₀ and lactate concentrations was obtained before drug treatment began. PTX (12.5 μM) was continuously infused for 12 h. After a 5 h washout period, TTX (5 μM) was continuously infused for 16 h before concluding the experiment. For ISF Aβ half-life experiments, a stable baseline of ISF Aβ₄₀ was obtained before intraperitoneally injecting each mouse with 10 mg kg⁻¹ of the γ-secretase inhibitor compound E (custom synthesis, AsisChem). The plot of the common logarithm of percent baseline ISF Aβ₄₀ concentration versus time after injection was linear in each region, suggesting first-order kinetics. Therefore, the elimination half-life of ISF Aβ₄₀ in each mouse was calculated using the slope of the linear regression from log(percent baseline ISF Aβ₄₀) versus time as described previously². In vibrissal trimming experiments, stable baseline concentrations of ISF Aβ₄₀ and ISF lactate were obtained before all mystacial vibrissae contralateral to the microdialysis probe were trimmed to within 1 mm of the facial pad using fine surgical scissors (Roboz). Vibrissae ipsilateral to the microdialysis probe remained intact throughout the experiment. In vibrissal stimulation experiments, mice were anesthetized with ketamine-xylazine (130.4 and 20.1 mg kg⁻¹, respectively) during the microdialysis sampling period. All vibrissae ipsilateral to the microdialysis probe were trimmed to
within 1 mm of the facial pad using fine surgical scissors (Roboz). Mechanical vibrissal stimulation was performed by gently brushing vibrissae contralateral to the microdialysis probe using a cotton-tipped applicator for 30 min (5–7 Hz, 4 s burst, 4 s inter-burst interval). In sleep/wake experiments, guide cannulae were implanted into hippocampus 2 weeks before microdialysis began. Mice were habituated to the microdialysis sampling environment for 3 d and microdialysis samples collected during this period were discarded. On the fourth day, samples were collected and stored for analysis.

**ELISA.**

Microdialysis samples were analyzed for Aβ$_{\text{x-40}}$, Aβ$_{\text{x-42}}$ or Aβ$_{1-\text{x}}$ using a species-specific sandwich enzyme-linked immunosorbent assay (ELISA). Briefly, Aβ$_{\text{x-40}}$, Aβ$_{\text{x-42}}$ and Aβ$_{1-\text{x}}$ were captured using monoclonal antibodies targeting amino acids 35–40 (HJ2, generated in-house), 37–42 (HJ7.4, generated in-house) and 13–28 (m266) of Aβ, respectively. For Aβ$_{\text{x-40}}$ and Aβ$_{\text{x-42}}$ assays, a biotinylated central-domain monoclonal antibody (HJ5.1, generated in-house) followed by streptavidin–poly-horseradish peroxidase-40 (Fitzgerald) was used for detection. For Aβ$_{1-\text{x}}$ assays, a biotinylated N-terminal-domain monoclonal antibody (3D6B) followed by streptavidin–poly-horseradish peroxidase-20 was used for detection (Fitzgerald). The antibodies m266 and 3D6B were generous gifts from Eli Lilly. All assays were developed using Super Slow ELISA TMB (Sigma) and read on a Bio-Tek Synergy 2 plate reader at 650 nm.

**Intraparenchymal EEG recording.**

Depth EEG recording was performed as previously described (Cirrito et al., 2005). Briefly, bipolar recording electrodes (A-M Systems) were affixed to the microdialysis
guide cannula and stereotaxically implanted into the hippocampus. Electrodes extended approximately 1 mm from the tip of the guide cannula to position the electrodes near the center of the 2-mm microdialysis membrane. EEG activity was assessed using a P511K A.C. preamplifier (Grass Technologies), digitized with a DigiData 1440A data acquisition system (Molecular Devices) and recorded digitally using pClamp 10.2 (Molecular Devices).

**Lactate assay.**

An enzymatic lactate assay kit (BioVision) was used to measure lactate present in ISF samples according to the manufacturer's instructions. Assays were read on a Bio-Tek Synergy 2 plate reader at 570 nm.

**Western blot.**

Dissected tissue from piriform, barrel and cingulate cortices was homogenized in radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM Tris, 0.5% (wt/vol) deoxycholic acid, 1% (vol/vol) Triton X-100, 0.1% (wt/vol) SDS, 2.5 mM EDTA and a protease inhibitor cocktail (Calbiochem), pH 8.0; 10 μl mg⁻¹ tissue wet weight) with a manual wand. Dissected tissue from hippocampus and striatum was homogenized in RIPA buffer by sonication. Tissue homogenates were centrifuged at 13,500 g at 4 °C for 15 min and supernatant was saved for analysis. In addition to normalizing western blot results to equal amounts of brain wet weight loaded per lane, a loading control was also performed for each tissue sample. Equal volumes of tissue samples were spiked with 5 μg fluorescein-conjugated BSA (Biosearch Technologies) to serve as a loading control and equal volumes of tissue homogenate were separated by 4–
12% Bis-Tris gel electrophoresis (Invitrogen) under reducing conditions. Nitrocellulose blots (0.2 μm pore size, Bio-Rad) were probed for full-length APP using 6E10 antibody (human-specific; Covance) or APP CTFs using CT695 antibody (reactivity with human and mouse; Invitrogen). Normalized band intensity was quantified using ImageJ (National Institutes of Health).

**Sleep/wake monitoring.**

Polysomnographic sleep-wake cycle analysis of mice was performed as described previously (Kang et al., 2009). Briefly, EEG and electromyogram (EMG) electrodes were implanted simultaneously with the microdialysis guide cannula. For EEG recording, two stainless steel screws attached to wire electrodes were placed over the right frontal bone (bregma + 1.0 mm, 1.5 mm lateral to midline) and the right parietal bone (bregma − 3.0 mm, 2.5 mm lateral to midline). Two wire electrodes were directly inserted into the neck musculature for EMG recording. The ground electrode was placed on the skull over the cerebellum. Insulated leads from the EEG and EMG electrodes were soldered to a mini-connector. After surgery, mice were housed in 12 h light/12 h dark conditions (light phase beginning at 6 a.m.) for 2 weeks before recording began. To monitor the sleep-wake cycle, mice were transferred to recording cages maintained in 12 h light/12 h dark conditions (light phase beginning at 6 a.m.) and the mini-connector was connected to flexible recording cables. Mice were habituated to the recording cages for 3 d. At the conclusion of the habituation period, EEG and EMG recording began simultaneously with microdialysis sample collection. EEG and EMG signals were displayed on a monitor and stored in a computer for off-line analysis of sleep states. EEG and EMG recordings were assessed using a P511K A.C. preamplifier (Grass Technologies), digitized with a
DigiData 1440A data acquisition system (Molecular Devices) and recorded digitally using pClamp 10.2 (Molecular Devices). EEG and EMG signals were filtered (EEG: high pass, 1 Hz; low pass, 30 Hz; EMG: high pass, 10 Hz; low pass, 100 Hz) and used to identify vigilance states. EEG and EMG recordings were scored semiautomatically using sleep scoring software (SleepSign, Kissei Comtec) and binned into 10-s epochs as wakefulness, rapid eye movement (REM) sleep and non-REM sleep per standard criteria of rodent sleep. Semiautomatic sleep scoring was visually inspected and corrected when appropriate.

**Thinned-skull cranial window surgery.**

Thinned-skull cranial windows were prepared on the day of the first multiphoton imaging session as described previously (Yan et al., 2009). Briefly, mice were anesthetized under volatile isoflurane and the skin and periosteum were removed to expose the skull. A high-speed drill and microsurgical blade (Surgistar) were used to thin the skull until it was transparent and flexible. One cranial window (2 × 2 mm) was prepared over barrel cortex (bregma −1.5 mm, 3.5 mm lateral to midline) of each hemisphere.

**In vivo multiphoton microscopy.**

Longitudinal multiphoton microscopy to monitor amyloid plaque growth was performed as described previously (Yan et al., 2009). Briefly, mice were injected intraperitoneally with the fluorescent amyloid-binding compound methoxy-X04 [(Klunk et al., 2002); 5 mg ml⁻¹] 24 h before each multiphoton imaging session. Mice were mounted on a custom-built stereotaxic apparatus and a small ring of molten bone wax was applied to the skull surrounding the perimeter of the window to create a water immersion chamber.
The cranial window was centered under the objective lens on a two-photon microscope (LSM 510 META NLO system (Carl Zeiss) with a Cameleon Ti:sapphire laser (Coherent Inc.)). Two-photon fluorescence was generated with 750 nm excitation and fluorescence emission was detected at 435–485 nm. A 10X water-immersion objective (numerical aperture 0.33, Zeiss) was used to create a site map during initial imaging and a 40X water-immersion objective (numerical aperture 0.75, Zeiss) was used for high-resolution quantification of individual amyloid plaques. Incremental z-stack image series (step distances 10 and 5 μm under 10X and 40X objectives, respectively) were acquired from the skull surface to approximately 200 μm into cortex. To determine the effect of long-term vibrissal deprivation on amyloid plaque formation and growth, the same sites of each hemisphere of barrel cortex in each mouse were imaged on day 0 and day 28. Collapsed z-stack images of each amyloid plaque were measured by cross-sectional area using SigmaScan Pro Image Analysis Software (Systat Software) as previously described (Yan et al., 2009). Plaques were excluded from analysis if they were located at the edge of the window or showed fluorescence intensity less than the mean intensity of an adjacent background region or if the image acquisition was affected by motion artifacts from heartbeat or respiration.

**Double immunofluorescence.**

To compare astrocytic and microglia activation in barrel cortex after long-term vibrissal deprivation, mice were transcardially perfused with 0.9% saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer immediately after the final multiphoton imaging session. Brains were removed and postfixed in 4% paraformaldehyde for another 4 h. Coronal free-floating sections (50 μm thick) were cut on a cryostat (Leica). Sections
were incubated overnight at 4 °C in a combination of mouse anti–glial fibrillary acidic protein monoclonal antibody (Sigma) and rabbit anti-Iba1 (Wako Chemicals). A secondary antibody mixture of Alexa Fluor 488–conjugated donkey anti–mouse IgG (Invitrogen) and Cy3-conjugated donkey anti–rabbit IgG (Jackson ImmunoResearch Laboratories) was used for detection. Sections were imaged using a confocal microscope (Zeiss LSM).

**Statistical analysis.**

Statistical significance was determined by two-tailed t-test if two groups were compared. When variance differed significantly between groups, Welch's t-test was used. One-way ANOVA followed by Tukey's *post hoc* test for multiple comparisons tests were used when more than two groups were compared. Correlation was determined using Pearson product moment correlation test. All statistical analyses were performed using Prism version 4.0 for Windows (GraphPad). Values were accepted as significant if $P < 0.05$. 


RESULTS

Regional plaque deposition in aged Tg2576 mouse brain

In Alzheimer's disease, amyloid deposition is most prominent in brain areas that comprise the default network. Core regions of the default network in human cortex include medial and lateral parietal, posterior cingulate, retrosplenial and medial prefrontal areas, as well as the hippocampal formation. To begin to elucidate the mechanisms that regulate region-specific amyloid deposition, we first characterized the distribution of Aβ deposition in APP transgenic (Tg2576) mice, which express a mutated form of amyloid precursor protein (APP). Brain sections from Tg2576 mice 17.5 ± 0.5 months old were immunostained with biotinylated 3D6 antibody, to Aβ amino acids 1-5 (anti-Aβ1-5) to determine the percentage area occupied by Aβ plaques in brain regions of interest. We found progressively higher Aβ plaque burden across barrel (3.96% ± 0.69), cingulate (9.00 ± 1.59) and piriform (16.54 ± 4.07) cortices (Fig. 1a–c). Aβ plaque burden in hippocampus (5.51 ± 1.45) was similar to that in barrel cortex; striatum (0.62 ± 0.11) had the least plaque deposition of all regions examined (Fig. 1a–c). Tg2576 mice thus show region-specific Aβ deposition that is similar to the pattern observed in human Alzheimer's disease.

To determine whether fibrillar amyloid plaques showed a distribution similar to Aβ immunopositive plaques, we stained brain sections from aged Tg2576 mice with the amyloid-specific dye X-34. In accord with the pattern of Aβ immunopositive plaque deposition, we found that the percentage area occupied by X-34–positive amyloid plaque deposition was progressively higher in barrel (0.27% ± 0.03), cingulate (1.22 ± 0.34) and
piriform (2.90 ± 0.40) cortices. Amyloid deposition in hippocampus (0.43 ± 0.09) was similar to that in barrel cortex. Amyloid was not detected in striatum (Fig. 1d–i). These results suggest that regional differences in Aβ and amyloid plaque deposition are present in aged Tg2576 mouse brain and that Tg2576 mice represent a useful model in which to examine mechanisms underlying regional vulnerability to Aβ and amyloid plaque deposition.

**ISF Aβ predicts region-specific plaque deposition**

As we have previously demonstrated that the concentration of Aβ in the ISF is closely associated with amyloid plaque growth and formation *in vivo*, we hypothesized that the steady-state concentration of ISF Aβ in each brain region early in life, before plaque deposition, would predict the degree of subsequent plaque deposition in aged mice. To test this hypothesis, we performed *in vivo* microdialysis to measure steady-state ISF Aβ in brain regions of young (age 3.5 ± 0.5 months) Tg2576 mice before the onset of plaque deposition. Using an Aβ<sub>x-40</sub>-specific ELISA, we found that steady-state ISF Aβ<sub>x-40</sub> concentrations were greatest in piriform cortex (2,296.55 ± 308.35 pg ml<sup>−1</sup>), intermediate in barrel cortex (824.16 ± 112.81) and hippocampus (1,150.10 ± 130.71) and lowest in striatum (184.74 ± 25.71; Fig. 2a). ISF Aβ<sub>x-40</sub> concentrations in young mice before plaque deposition therefore predict the amount of both Aβ (Fig. 2b) and fibrillar amyloid (Fig. 2c) plaque deposition in aged mice in a region-specific manner. We next sought to determine whether the concentration of the more amyloidogenic form of Aβ, Aβ<sub>x-42</sub>, in each brain region of young mice predicts the level of plaque deposition in aged mice. Consistent with our data regarding regional ISF Aβ<sub>x-40</sub> concentrations, an Aβ<sub>x-42</sub>-specific ELISA showed that ISF Aβ<sub>x-42</sub> concentration was greatest in piriform cortex (104.94 ±
30.21 pg ml\(^{-1}\)), intermediate in barrel cortex (48.24 ± 6.79) and hippocampus (44.31 ± 8.25) and lowest in striatum (9.47 ± 1.46; Fig. 2d). Therefore, regional ISF Aβ\(_{x-42}\) concentration in young mice also predicts the degree of regional Aβ (Fig. 2e) and amyloid (Fig. 2f) plaque deposition in aged mice.

Next, we assessed whether regional differences in ISF Aβ levels were present in young wild-type (B6SJL) mice. In accord with our findings in APP transgenic mice, mouse ISF Aβ\(_{x-40}\) concentrations were significantly greater in hippocampus (148.51 ± 17.93 pg ml\(^{-1}\)) than in striatum (47.4 ± 11.46; \(P = 0.0032;\) Supplementary Fig. 1a). This result suggests that regional differences in ISF Aβ concentration are intrinsic to normal brain physiology. Together, these data suggest that steady-state ISF Aβ levels in young mice predict the degree of Aβ and amyloid plaque deposition in a region-specific manner.

**ISF lactate predicts region-specific ISF Aβ**

As the default network shows elevated cerebral metabolism during resting conditions, one possibility is that elevated metabolic activity in specific brain regions throughout life regulates the ultimate distribution of amyloid deposition. Previous data suggest that synaptic activity regulates soluble extracellular Aβ levels *in vitro* and *in vivo*. As ISF Aβ concentration is closely associated with amyloid plaque growth and formation, we hypothesized that regional differences in baseline neuronal activity would be proportional to regional steady-state ISF Aβ concentration in Tg2576 mice before the onset of plaque deposition. Previous data suggest that neuronal activity directly regulates extracellular lactate concentration *in vitro* (Pellerin and Magistretti, 1994) and *in vivo* (Uehara et al., 2008). To further establish ISF lactate as a marker of neuronal activity, we
pharmacologically manipulated neuronal activity during in vivo microdialysis with concurrent intraparenchymal electroencephalogram (EEG) recording in young Tg2576 mice. To determine whether increased neuronal activity increases ISF lactate and Aβ, we administered picrotoxin (12.5 μM; PTX), a GABA_A receptor antagonist, by means of reverse microdialysis. Infusion of PTX into hippocampus increased hippocampal EEG amplitude (Fig. 3a) and ISF lactate compared to basal conditions (PTX, 129.6 ± 6.4% of basal; basal, 100.0 ± 8.76; \( P = 0.0342 \); Fig. 3b and Supplementary Fig. 2a). In accord with previous data (Cirrito et al., 2008), PTX also significantly increased hippocampal ISF Aβ_{42} concentration relative to basal conditions (PTX, 125.8 ± 5.16% of basal; basal, 100.0 ± 5.21; \( P = 0.0126 \); Fig. 3c and Supplementary Fig. 2b). To determine whether depression of local neuronal activity reduces ISF lactate and Aβ, we administered the voltage-gated sodium channel blocker tetrodotoxin (5 μM; TTX) by means of reverse microdialysis. Compared to basal conditions, TTX reduced EEG amplitude (Fig. 3a) and ISF lactate in hippocampus (TTX, 69.62 ± 2.69% of basal; basal, 100.0 ± 8.75; \( P = 0.0160 \); Fig. 3b and Supplementary Fig. 2a). Consistent with previous data (Cirrito et al., 2005), TTX infusion also reduced ISF Aβ_{42} concentration (TTX, 67.11 ± 2.94% of basal; basal, 100.0 ± 5.21; \( P = 0.0015 \); Fig. 3c and Supplementary Fig. 2b). Across basal, PTX treatment and TTX treatment conditions, ISF lactate significantly correlated with ISF Aβ (Pearson \( r = 0.7645 \), \( P < 0.0001 \); Fig. 3d). Together, these data suggest that increasing neuronal activity increases, and decreasing neuronal activity decreases, ISF lactate concentration and suggest that ISF lactate is a marker of neuronal activity in vivo.

To test the hypothesis that regional differences in ISF lactate are proportional to regional steady-state ISF Aβ concentration before the onset of plaque deposition, we next
performed in vivo microdialysis to measure steady-state ISF lactate in several brain regions of young Tg2576 mice. We found that ISF lactate was greatest in piriform cortex (142.47 ± 10.19% of striatal value), intermediate in barrel cortex (124.94 ± 11.58) and hippocampus (119.3 ± 10.53) and lowest in striatum (100.0 ± 11.93). ISF lactate was thus commensurate with steady-state ISF Aβ40 (Fig. 4a) and Aβ42 (Fig. 4b) concentrations in young Tg2576 mice. Moreover, steady-state ISF lactate was proportional to subsequent Aβ (Fig. 4c) and amyloid (Fig. 4d) plaque deposition on a region-specific basis. To test whether the relationship between basal ISF lactate and ISF Aβ also held in wild-type mice, we measured ISF lactate in hippocampus and striatum of young B6SJL mice. In accord with our data in Tg2576 mice, ISF lactate concentration was closely associated with mouse ISF Aβ40 concentration in young B6SJL mice (Supplementary Fig. 1b). These results suggest that regional differences in ISF lactate in young mice before plaque deposition are closely associated with steady-state ISF Aβ concentration and subsequent plaque deposition in Tg2576 mice.

As steady-state ISF Aβ concentration is the result of a balance between the rates of Aβ production and clearance, we next sought to determine whether regional differences in ISF Aβ clearance rate might be associated with steady-state ISF Aβ levels in young Tg2576 mice and might therefore contribute to region-specific Aβ deposition. To assess this possibility, we performed in vivo microdialysis in several brain regions of young Tg2576 mice. During the microdialysis sampling period, mice were treated intraperitoneally with compound E (10 mg per kilogram body weight), a potent γ-secretase inhibitor, to rapidly halt Aβ synthesis and permit determination of ISF Aβ elimination half-life ($t_{1/2}$) as previously described (Cirrito et al., 2003). ISF Aβ40 $t_{1/2}$ did
not differ significantly across barrel cortex (0.99 ± 0.11 h), hippocampus (0.97 ± 0.03) and striatum (1.21 ± 0.08; $P = 0.1175$) in the brains of young Tg2576 mice (Supplementary Fig. 3a,b), suggesting that regional variation in ISF Aβ clearance rate is not sufficient to account for the pattern of plaque deposition in aged Tg2576 mice.

**APP processing does not predict regional ISF Aβ levels**

Amyloidogenic processing of full-length APP by β- and γ-secretase is necessary for Aβ generation. β-secretase cleavage of APP holoprotein produces C-terminal fragment (CTF)-β, whereas non-amyloidogenic processing of APP by α-secretase produces CTF-α and precludes Aβ generation. Differential expression or processing of APP holoprotein across brain regions could thus contribute to regional differences in steady-state ISF Aβ concentrations and plaque deposition. To test this possibility, we performed western blot analyses to measure APP holoprotein, CTF-β and CTF-α across cortical regions that harbor differential ISF Aβ concentrations and develop differential plaque burden. Despite marked differences in steady-state ISF Aβ concentrations and plaque deposition, expression levels of full-length APP, CTF-β and CTF-α were similar in piriform, cingulate and barrel cortices ($P = 0.9437, 0.9821$ and $0.6348$ for APP, CTF-β and CTF-α, respectively; Supplementary Fig. 4a–c).

To determine the role of APP expression and processing in region-specific regulation of Aβ concentration in subcortical structures, we next measured APP holoprotein, CTF-β and CTF-α in whole cortex, hippocampus and striatum. Relative to hippocampus and striatum, APP holoprotein expression was significantly greater in cortex ($P = 0.0017$; Supplementary Fig. 4d,f). CTF-β expression was significantly lower in striatum than in
hippocampus ($P = 0.0245$; Supplementary Fig. 4e,f), whereas CTF-α expression did not differ across cortex, hippocampus and striatum ($P = 0.9761$; Supplementary Fig. 4e,f). Together, these results suggest that regional APP expression and processing profiles are not associated with local differences in steady-state ISF Aβ or plaque deposition and are thus not sufficient to account for the pattern of amyloid deposition observed in Tg2576 mice.

**Vibrissal activity regulates ISF Aβ levels**

The present data suggest that regional differences in basal ISF lactate concentrations are closely associated with steady-state ISF Aβ concentrations and predict subsequent plaque deposition. We next sought to determine whether a causal relationship between physiological neuronal activity and both steady-state ISF Aβ and lactate concentrations exists *in vivo*. In rodents, each vibrissa is somatotopically mapped onto a defined cluster of neurons termed a 'barrel' in primary somatosensory cortex (Woolsey and Van der Loos, 1970). There, neurons in each barrel respond to stimulation of the vibrissa to which they are synaptically connected. Vibrissal stimulation increases (Melzer et al., 1985), whereas vibrissal removal decreases (Durham and Woolsey, 1978), neuronal activity in barrel cortex. Therefore, the vibrissae-barrel system represents a noninvasive physiological circuit in which to examine the relationship between physiological neuronal activity and ISF Aβ concentrations *in vivo*.

To determine whether a manipulation that causes a physiological reduction in neuronal activity could reduce ISF Aβ concentrations, we performed vibrissal deprivation during *in vivo* microdialysis in barrel cortex of young Tg2576 mice. After establishing stable
basal ISF Aβ concentrations, we trimmed all vibrissae contralateral to the microdialysis probe to within 1 mm of the facial pad. Acute trimming of vibrissae reduced ISF Aβ in barrel cortex by 22% compared to baseline ($P = 0.0107$; Fig. 5a,c). Similarly, trimming of vibrissae reduced ISF lactate in barrel cortex by 19% relative to basal conditions ($P = 0.0127$; Fig. 5b,c).

To determine whether a manipulation that causes a physiological increase in neuronal activity is sufficient to increase ISF Aβ concentrations, we next performed unilateral mechanical vibrissal stimulation during *in vivo* microdialysis in barrel cortex of a separate cohort of young Tg2576 mice anesthetized with ketamine-xylazine. Ketamine-xylazine was chosen as the anesthetic agent because both basal and vibrissal stimulation–induced neurophysiological responses under ketamine-xylazine anesthesia resemble the responses elicited during wake and quiet sleep more closely than under other forms of anesthesia (Rojas et al., 2006). We found that unilateral mechanical vibrissal stimulation (5–7 Hz, 4 s burst, 4 s inter-burst interval) for 30 min increased ISF Aβ$_{x-40}$ in barrel cortex by 31% relative to control conditions ($P = 0.0446$; Fig. 5d).

**ISF lactate levels show diurnal fluctuation**

The sleep/wake cycle is associated with diurnal fluctuation of ISF Aβ; ISF Aβ concentration is greater during wakefulness and lesser during sleep (Kang et al., 2009). Previous data from humans and animal models suggest that periods of wakefulness are associated with increased synaptic strength and periods of sleep are associated with decreased synaptic strength (Riedner et al., 2007; Vyazovskiy et al., 2008b; Gilestro et
al., 2009). Therefore, we reasoned that diurnal fluctuation of ISF Aβ might be linked with lactate levels throughout the sleep/wake cycle.

To assess this possibility, we performed in vivo microdialysis in hippocampi of young Tg2576 mice housed in 12 h light/12 h dark conditions. Consistent with our previous findings, ISF Aβ₁₋₄ concentrations were 21% greater during the dark period than during the light period ($P = 0.0314$; Fig. 6a,c). Moreover, ISF lactate concentrations were 23% greater during the dark period than during the light period ($P = 0.0066$; Fig. 6b,c). ISF Aβ₁₋₄ concentrations were thus correlated with ISF lactate concentrations across the sleep/wake cycle (Pearson $r = 0.6351$, $P < 0.0001$; Fig. 6d). As mice spent significantly more time awake during the dark period than during the light period (dark, 51.32 ± 1.26 min awake per hour; light, 25.02 ± 2.15; $P < 0.0001$), these findings suggest that wakefulness, ISF lactate and ISF Aβ are co-regulated and are consistent with the hypothesis that diurnal fluctuation in neuronal activity contributes to the diurnal fluctuation in ISF Aβ in vivo.

**Vibrissal deprivation reduces plaque formation and growth**

We have previously demonstrated that the concentration of ISF Aβ is closely related to amyloid plaque growth and formation in vivo (Yan et al., 2009). As our present data suggest that acute manipulations that alter neuronal activity modulate ISF Aβ concentration, we hypothesized that manipulations that cause longer-term changes in neuronal activity might modulate amyloid plaque growth and formation in vivo. To test this hypothesis, we used 7-month-old APPswe; PSEN1ΔE9 [APP/PS1; (Jankowsky et al., 2004)] bitransgenic mice because this strain develops aggressive fibrillar amyloid
deposition beginning at 4–5 months of age. Using \textit{in vivo} multiphoton microscopy, amyloid plaques in barrel cortex of each hemisphere were visualized with methoxy-X04 under thinned-skull cranial windows to obtain basal measures of individual amyloid plaque size. All vibrissae on the right side of the facial pad were subsequently trimmed to within 1 mm of the face every other day for 28 d. At the conclusion of the 28-d vibrissal deprivation period, amyloid plaques in barrel cortex of each hemisphere were reimaged to assess the effect of vibrissal deprivation on individual amyloid plaque growth. We found that plaque growth was decreased by 78\% in the vibrissae-deprived relative to the control hemisphere ($P = 0.0014$; Fig. 7a–e). Moreover, new amyloid plaque formation was decreased by 65\% in the deprived relative to the control hemisphere ($P = 0.0367$; Fig. 7a–d,f).

To determine whether suppression of amyloid plaque growth and formation upon long-term vibrissal deprivation might be attributable to increased glial activation in barrel cortex, brains were sectioned and stained for glial fibrillary acidic protein and Iba-1 to visualize astrocytic and microglial activation, respectively. Confocal microscopy revealed no qualitative difference in astrocytic (Supplementary Fig. 5a–c) or microglial (Supplementary Fig. 5d–f) activation in the deprived hemisphere compared to the control hemisphere. This result suggests that altered glial activation is not likely to contribute to the observed suppression of amyloid plaque growth and formation upon long-term vibrissal deprivation. Taken together, although long-term vibrissal deprivation results in several changes in the brain, the present data are consistent with the hypothesis that physiological neuronal activity regulates amyloid plaque growth dynamics \textit{in vivo}.  

DISCUSSION

Aggregation of Aβ into higher-order structures such as extracellular amyloid plaques is a necessary event in Alzheimer's disease pathogenesis. A fundamental feature of Alzheimer's disease is the preferential deposition of amyloid plaques in distinct brain regions. However, the mechanism by which specific brain regions are rendered vulnerable to amyloid deposition in Alzheimer's disease has heretofore remained unknown. As Aβ aggregation is closely related to ISF Aβ concentration \textit{in vivo}, elucidating the mechanisms that regulate ISF Aβ concentration has important implications for understanding the etiology of region-specific Aβ deposition in Alzheimer's disease. In the present work, we used \textit{in vivo} microdialysis to show that ISF Aβ concentrations measured in several brain regions of young Tg2576 mice months before plaque deposition are directly proportional to the degree of subsequent plaque deposition. Moreover, ISF Aβ concentrations in young mice are closely associated with concentrations of baseline ISF lactate, a marker of neuronal activity, on a region-specific basis. Furthermore, we show that physiological changes in neuronal activity are sufficient to dynamically modulate ISF Aβ concentrations and amyloid plaque growth \textit{in vivo}.

Collectively, our results suggest that regional differences in basal neuronal activity level govern region-specific amyloid deposition through long-term regulation of steady-state ISF Aβ concentration.

As sequential proteolysis of APP by β- and γ-secretase is necessary for Aβ generation, several previous reports have examined the regional distribution of this triad as potential mediators of region-specific Aβ deposition. However, the cerebral distribution of \textit{APP}, \textit{BACE1} and \textit{PSEN1} transcripts is not associated with the topography of Aβ deposition in
human Alzheimer's disease (Bahmanyar et al., 1987; Goedert, 1987; Page et al., 1996; Vassar et al., 1999) or APP transgenic mice (Irizarry et al., 1997; Bigl et al., 2000; Irizarry et al., 2001). Moreover, the regional distribution of $\gamma$-secretase activity in APP transgenic mouse brain does not correlate with the pattern of $\alpha\beta$ deposition (Goldstein et al., 2007). Consistent with these previous reports, the present results suggest that although differences in APP expression and processing are present across a subset of brain areas in Tg2576 mice, the pattern of APP expression and processing is not sufficient to account for the pattern of $\alpha\beta$ deposition. Together, these studies suggest that more factors are necessary to drive region-specific $\alpha\beta$ deposition. In addition to region-specific differences in neuronal activity potentially contributing to region-specific differences in $\alpha\beta$ deposition, other possible contributors to the presence of $\alpha\beta$ in specific neural networks include the spread of $\alpha\beta$ aggregates within and into the brain. For instance, exogenous intracerebral (Meyer-Luehmann et al., 2003; Meyer-Luehmann et al., 2006) or peripheral (Eisele et al., 2010) application of $\alpha\beta$ aggregates can seed cerebral $\beta$-amyloidosis. Further, reports suggest that selective overexpression of APP in the cell bodies of neurons in the entorhinal cortex of transgenic mice can elevate soluble $\alpha\beta$ and produce amyloid plaque deposition in the synaptic terminal zone of the dentate gyrus (Lazarov et al., 2002; Harris et al., 2010). Thus, transsynaptic propagation mechanisms as well as spread of $\alpha\beta$ pathology through interconnected neural networks might also contribute to the pattern of amyloid deposition observed in Alzheimer's disease.

In the healthy human brain, a specific subset of brain regions—the default network—is preferentially engaged during resting the state. Notably, amyloid deposition in
Alzheimer's disease brain is most prominent in regions that comprise the default network. These findings raise the possibility that patterns of normal cerebral metabolism may influence the distribution of amyloid deposition in Alzheimer's disease. In accord with this hypothesis, recent data suggest that the spatial distribution of resting-state aerobic glycolysis (that is, glucose utilization in excess of that used for oxidative phosphorylation despite sufficient oxygen to oxidize glucose to carbon dioxide and water) in cognitively normal adults overlaps closely with the topography of amyloid deposition in Alzheimer's disease. Our present data demonstrating that pharmacological manipulation of neuronal activity directly regulates ISF lactate abundance are consistent with previous animal and human studies and suggest that neuronal activity stimulates aerobic glycolysis in vivo. Given that neuronal activity also increases Aβ production and secretion into the ISF, regional differences in neuronal activity may underlie the spatial relationship between resting-state aerobic glycolysis and amyloid deposition in Alzheimer's disease.

We have previously demonstrated that ISF Aβ concentrations fluctuate diurnally: ISF Aβ concentration is significantly greater during waking conditions than during sleep (Kang et al., 2009). Given that neuronal activity directly regulates ISF Aβ levels, we reasoned that diurnal fluctuation of neuronal activity may contribute to diurnal fluctuation of ISF Aβ. Indeed, previous data suggest that periods of wakefulness are associated with net synaptic potentiation and periods of sleep are associated with synaptic downscaling and depression (Vyazovskiy et al., 2008b). Here we show that ISF lactate concentration fluctuates diurnally in a manner closely associated with the diurnal fluctuation of ISF Aβ. These results are consistent with the notion that fluctuation of neuronal activity during the sleep/wake cycle contributes to the diurnal fluctuation of ISF Aβ in vivo. This
observation further supports the hypothesis that physiological neuronal activity
dynamically regulates ISF Aβ levels in vivo.

More generally, our results suggest that factors that elevate endogenous neuronal activity
over prolonged periods may accelerate progression of Aβ deposition. In support of this
hypothesis, recent functional magnetic resonance imaging data suggest that cognitively
normal apolipoprotein E (APOE) allele ε4 carriers show elevated resting-state activity in
the default network and increased hippocampal activation during a memory encoding
task compared to noncarriers (Filippini et al., 2009). Thus, in addition to apoE isoform–
dependent differences in apoE-Aβ interactions (Kim et al., 2009a), elevated lifetime
neuronal activity may be a complementary mechanism by which ε4 expression increases
Alzheimer's disease risk. Conversely, factors that reduce activity in vulnerable neural
networks may slow the progression of β-amyloidosis and reduce Alzheimer's disease risk.
For example, epidemiological evidence suggests that educational attainment is negatively
correlated with Alzheimer's disease risk (Flicker, 2010). As default network activity is
suppressed during cognitively demanding tasks, one possibility is that education reduces
Alzheimer's disease risk by reducing neuronal activity and Aβ generation within the
default network.

It is noteworthy that the regional distribution of lesions in mouse models of glutamate-
induced excitotoxicity is similar to the distribution of Aβ deposition described herein
(Olney et al., 1997). As neuronal activity regulates both Aβ and glutamate release at the
synapse, the regional differences in basal neuronal activity described here may also
underlie the distribution of glutamate-induced excitotoxic lesions. A more detailed
understanding of the regional distribution of pre- and postsynaptic elements may provide
insight regarding the structural basis of neuronal activity patterns in normal brain and how patterns of neuronal and synaptic activity might contribute to a variety of neurological lesions.
Figure 1. Distribution of Aβ and amyloid plaque deposition in Tg2576 mouse brain. 

(a,b) Representative brain sections from aged (17.5 ± 0.5 months old) Tg2576 mice stained with biotinylated 3D6 antibody (anti-Aβ1–5) to visualize Aβ immunopositive plaques (n = 7 per group). Scale bar, 750 μm. 
(c) Percentage brain area occupied by Aβ deposition in barrel (BC), cingulate (CC) and piriform (PC) cortices and hippocampus (HC) and striatum (ST). (d–h) Representative images of barrel cortex (d), cingulate cortex (e), piriform cortex (f), hippocampus (g) and striatum (h) of aged Tg2576 mice stained with the amyloid-binding dye X-34 (n = 6 per group). Scale bar, 50 μm. 
(i) Percentage area occupied by X-34–positive amyloid deposition in brain regions examined. *P < 0.05; **P < 0.01; ***P < 0.001 (one-way analysis of variance (ANOVA), Tukey's post hoc test for multiple comparisons). Values represent mean ± s.e.m.
Figure 2. Steady-state ISF Aβ concentrations in young Tg2576 mice before plaque deposition are associated with the level of region-specific plaque deposition in aged Tg2576 mice. (a) In vivo microdialysis measurements of the steady-state concentrations of ISF Aβx–40 in barrel cortex (BC), piriform cortex (PC), hippocampus (HC) and striatum (ST) of 3.5 ± 0.5-month-old Tg2576 mice before the onset of plaque deposition (n = 5–6 per group; one-way ANOVA, Tukey’s post hoc test for multiple comparisons). (b,c) Steady-state concentrations of ISF Aβx–42 measured in each brain region of young Tg2576 mice, plotted against subsequent Aβ (b) and amyloid (c) plaque deposition in each brain region of aged Tg2576 mice. (d) In vivo microdialysis measurements of the steady-state concentration of ISF Aβx–42 in barrel cortex (●), piriform cortex (●), hippocampus (○) and striatum (○) of 3.5 ± 0.5-month-old Tg2576 mice before the onset
of plaque deposition \((n = 5–8\) per group; one-way ANOVA, Tukey's post hoc test for multiple comparisons). (e,f) Steady-state concentrations of ISF Aβ<sub>x–42</sub> measured in each brain region of young Tg2576 mice, plotted against subsequent Aβ (e) and amyloid (f) plaque deposition in each brain region of aged Tg2576 mice. *\(P < 0.05\); **\(P < 0.01\); ***\(P < 0.001\). Values represent mean ± s.e.m.
Figure 3. Neuronal activity regulates ISF lactate concentration in vivo. (a) Representative intraparenchymal EEG recordings from hippocampus of young Tg2576 mice during basal conditions, picrotoxin (PTX; 12.5 μM) treatment or tetrodotoxin (TTX; 5 μM) treatment by means of in vivo microdialysis (n = 4 per group). (b) Effect of local PTX or TTX infusion on ISF lactate in hippocampus of young Tg2576 mice (n = 4 per group; two-tailed t-test). (c) Effect of local PTX or TTX infusion on ISF Aβx–40 in hippocampus of young Tg2576 mice (n = 4 per group; two-tailed t-test). Values in b,c represent analyte concentrations during the final 6 h of drug treatment. (d) ISF lactate concentrations were correlated with ISF Aβx–40 concentrations across treatment periods (Pearson r = 0.7645; P < 0.0001). *P < 0.05; **P < 0.01. Values represent mean ± s.e.m.
Figure 4. Steady-state ISF lactate levels in young Tg2576 mice are closely associated with regional ISF Aβ levels in young Tg2576 mice and plaque deposition in aged Tg2576 mice. (a–d) In vivo microdialysis measurements of steady-state ISF lactate concentrations (expressed as a percentage of the striatal value) in barrel cortex (●), piriform cortex (○), hippocampus (●), and striatum (●) of young Tg2576 mice (n = 6–7 per group). ISF lactate concentration in each brain region is plotted against concentration of ISF Aβ_{40} (a) and ISF Aβ_{42} (b) in each brain region of young Tg2576 mice. ISF lactate concentration in each brain region of young Tg2576 mice is also plotted against Aβ (c) and amyloid (d) plaque deposition in each brain region of aged Tg2576 mice. Values represent mean ± s.e.m.
Figure 5. Vibrissal activity regulates ISF Aβ levels in vivo. (a–c) Effect of vibrissal deprivation on ISF Aβ$_{x-40}$ (a, black bars in c) and lactate (b, white bars in c) concentrations relative to baseline ($n = 6–7$; two-tailed $t$-test). In vivo microdialysis was performed in posterior barrel cortex of young Tg2576 mice. After establishing stable basal ISF Aβ$_{x-40}$ and lactate concentrations, all vibrissae contralateral to the microdialysis probe were trimmed to within 1 mm of the facial pad and microdialysis sample collection continued for 16 h. (d) Effect of vibrissal stimulation on ISF Aβ$_{x-40}$ concentrations compared to control conditions ($n = 4$; two-tailed $t$-test). In vivo microdialysis was performed in barrel cortex in a separate cohort of young Tg2576 mice that underwent subsequent unilateral vibrissal stimulation. Baseline Aβ$_{x-40}$ values were obtained for a 30-min period. Unilateral mechanical stimulation of vibrissae contralateral to the
microdialysis probe was performed for 30 min. *$P < 0.05$. Values represent mean ± s.e.m.
Figure 6. Diurnal fluctuation of ISF Aβ is closely associated with ISF lactate levels.

(a–c) In vivo microdialysis measurements from hippocampi of young Tg2576 mice housed in 12 h light/12 h dark conditions. ISF Aβ$_{1-x}$ (a; black bars in c) and lactate (b; white bars in c) concentrations were sampled throughout the light/dark cycle (n = 6; two-tailed t-test). (d) ISF Aβ$_{1-x}$ concentrations plotted against ISF lactate concentrations throughout the sleep/wake cycle (Pearson $r = 0.6351; P < 0.0001$). *$P < 0.05$; **$P < 0.01$. Values represent mean ± s.e.m.
Figure 7. Vibrissal deprivation reduces amyloid plaque growth and formation in vivo. (a,b) Representative multiphoton micrographs of individual amyloid plaques in barrel cortex in control hemisphere of APP/PS1 mice before (a) and after (b) 28 d of unilateral vibrissal deprivation. (c,d) Representative multiphoton micrographs of amyloid plaques in barrel cortex in vibrissae-deprived hemisphere of APP/PS1 mice before (c) and after (d) 28 d of vibrissal deprivation. (e,f) Quantification of mean plaque growth (e) and new plaque formation (f) in vibrissae-deprived and control hemispheres (n = 6 mice; two-tailed t-test). Arrows, existing amyloid plaques; arrowhead, newly formed amyloid plaque. Scale bar, 50 μm; *P < 0.05; **P < 0.01. Values represent mean ± s.e.m.
Supplementary Figure 1. Regional ISF Aβ and lactate levels in wild-type (B6SJL) mice. (a) In vivo microdialysis was performed in hippocampus and striatum of 5.5 ± 0.5 month-old wild-type (B6SJL) mice. Murine ISF Aβ₄₀ levels were significantly greater in hippocampus compared to striatum (n = 4 per group; two-tailed t-test). (b) Murine ISF Aβ₄₀ levels were closely associated with ISF lactate levels in a region-specific manner (n = 4). ◊, striatum; ○, hippocampus. **, P < 0.01. Values represent mean ± SEM.
Supplementary Figure 2. Time course of picrotoxin and tetrodotoxin treatment on ISF Aβ_{x-40} and lactate levels in hippocampus. (a,b) Young (3.5 ± 0.5 month-old) Tg2576 mice were treated sequentially with picrotoxin (12.5 μM; PTX) and tetrodotoxin (5 μM; TTX) via reverse microdialysis during the microdialysis sampling period. (a) ISF lactate and (b) Aβ_{x-40} levels were increased during PTX treatment and decreased during TTX treatment (n = 4 per group). Values represent mean ± SEM.
Supplementary Figure 3. ISF Aβ_{x-40} clearance rates across brain regions of young Tg2576 mouse brain. (a, b) After baseline ISF Aβ_{x-40} levels were established, young (3.5 ± 0.5 month-old) Tg2576 mice were treated with a potent γ-secretase inhibitor, Compound E (CPE; 10 mg kg⁻¹), during the microdialysis sampling period to halt Aβ synthesis and permit ISF Aβ_{x-40} t_{1/2} determination. ISF Aβ_{x-40} t_{1/2} did not differ across barrel cortex (BC), hippocampus (HC) and striatum (ST; n = 4 per group; one-way ANOVA, Tukey’s post hoc test for multiple comparisons). ○, barrel cortex; ■, hippocampus; Δ, striatum. Values represent mean ± SEM.
Supplementary Figure 4. APP expression and processing are not associated with regional ISF Aβ levels or plaque deposition. (a–c) Piriform (PC), cingulate (CC) and barrel (BC) cortices were dissected from fresh brain sections (500 μm thick) of young (3.5 ± 0.5 month-old) Tg2576 mice. Dissected tissue samples were analyzed for expression of (a) full-length APP, (b) CTF-β and CTF-α by western blot analysis. APP and CTF expression in each lane was normalized to fluorescein-conjugated bovine serum albumin (Fl-BSA) loading control. (c) Expression of APP, CTF-β and CTF-α did not differ across piriform, cingulate and barrel cortices (n = 6 per group; one-way ANOVA, Tukey’s post hoc test for multiple comparisons). (d–f) Whole cortex (CTX), hippocampus (HC) and striatum (ST) were dissected from fresh brain tissue of young (3.5 ± 0.5 month-old) Tg2576 mice. Dissected tissue samples were analyzed for expression of (d) full-length APP, (e) CTF-β and CTF-α by western blot analysis. APP and CTF expression in each lane was normalized to Fl-BSA loading control. (f) Expression of full-length APP was significantly greater in cortex compared to hippocampus and striatum.
CTF-β expression was greater in hippocampus compared to striatum. CTF-α expression did not differ significantly across brain regions ($n = 7$ per group; one-way ANOVA, Tukey’s post hoc test for multiple comparisons). ■, full-length APP; ■, CTF-β; □, CTF-α. *, $P < 0.05$; **, $P < 0.01$. Panels a,b,d,e contain cropped blots. Values represent mean ± SEM.
Supplementary Figure 5. Glial activation in barrel cortex following long-term vibrissae deprivation. (a) Low-power image of a representative brain section from an APP/PS1 (7–7.5 months old) mouse that underwent 28-day unilateral vibrissae deprivation stained with an anti-GFAP antibody to visualize astrocytes (green) and counter-stained with X-34 to visualize amyloid plaque deposition (blue). No clear difference in GFAP staining was evident between vibrissae-deprived (left; b) and control (right; c) hemispheres (n = 6). (d) Low-power image of a representative brain section from an APP/PS1 (7–7.5 months old) mouse that underwent 28 day unilateral vibrissae deprivation stained with an anti-Iba-1 antibody to visualize microglia (red) and counter-stained with X-34 to visualize amyloid plaque deposition (blue). No clear difference in Iba-1staining was present between vibrissae-deprived (left; e) and control (right; f) hemispheres (n = 6). White rectangles in a,d denote barrel cortex. Scale bars in a,d, 1 mm; scale bars in b,e, 50 μM.
Chapter 4.

Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain
PREFACE

Adam W. Bero and Adam Q. Bauer (laboratory of Joseph P. Culver) contributed equally to the work in this chapter. Floy Stewart provided technical assistance.
ABSTRACT

Brain region-specific deposition of amyloid plaques principally composed of extracellular aggregates of amyloid-β (Aβ) peptide is a pathological signature of Alzheimer’s disease (AD). Recent human neuroimaging data suggest that resting-state functional connectivity strength is reduced in patients with AD, cognitively normal elderly harboring elevated amyloid burden, and in advanced aging. Interestingly, there exists a striking spatial correlation between functional connectivity strength in cognitively normal adults and the location of Aβ plaque deposition in AD. However, technical limitations have heretofore precluded examination of the relationship between functional connectivity, Aβ plaque deposition, and normal aging in mouse models. Using a novel functional connectivity optical intrinsic signal (fcOIS) imaging technique, we demonstrate that the magnitude of regional bilateral functional correlation in young APP/PS1 mice prior to Aβ plaque formation was proportional to the amount of region-specific plaque deposition seen later in older APP/PS1 mice. Furthermore, we found that Aβ plaque deposition is associated with significantly reduced bilateral functional connectivity in retrosplenial, frontal, cingulate, and motor cortices of older APP/PS1 transgenic mice. The degree of Aβ plaque deposition in each brain region was associated with local bilateral functional connectivity decline. Normal aging was associated with reduced bilateral functional connectivity specifically in retrosplenial cortex. Together, these findings suggest that the magnitude of local bilateral functional connectivity predicts regional vulnerability to subsequent Aβ plaque deposition and that Aβ plaque deposition and normal aging are associated with region-specific disruption of functional connectivity in mouse brain.
INTRODUCTION

Alzheimer’s disease (AD) is the most common cause of dementia, characterized by progressive structural and functional deterioration of higher-order neural networks. A histopathological hallmark of AD is the presence of extracellular plaques primarily composed of aggregated amyloid-β (Aβ) peptide. Under normal conditions, Aβ is produced in neurons and is present in the extracellular space of the brain in soluble form (Selkoe, 2001). During AD pathogenesis, soluble Aβ aggregates into Aβ oligomers and insoluble extracellular amyloid plaques in a concentration-dependent manner (Yan et al., 2009; Bero et al., 2011). In AD, amyloid plaque deposition is most prominent in the default-mode network, a network of brain areas in which metabolism is preferentially elevated during undirected mentation (Raichle et al., 2001; Buckner et al., 2005; Raichle and Mintun, 2006; Vaishnavi et al., 2010; Vlassenko et al., 2010). Interestingly, functional connectivity MRI (fcMRI) studies show that multiple regions of the default-mode network exhibit high intrinsic functional connectivity in healthy brain (Hagmann et al., 2008; Buckner et al., 2009). Moreover, recent data suggest that the relationship between functional connectivity and AD is bidirectional, as functional connectivity is disrupted in patients with AD (Supekar et al., 2008; Zhang et al., 2009), cognitively normal elderly with elevated amyloid burden (Hedden et al., 2009; Sheline et al., 2010a; Drzezga et al., 2011), and in advanced aging (Andrews-Hanna et al., 2007).

In mouse models of β-amyloidosis, Aβ plaque deposition is associated with myriad neurotoxic effects, including neuritic dystrophy, impaired synaptic integration and calcium dyshomeostasis (Knowles et al., 1999; D'Amore et al., 2003; Lombardo et al., 2003; Tsai et al., 2004; Brendza et al., 2005; Garcia-Alloza et al., 2006; Kuchibhotla
et al., 2008; Meyer-Luehmann et al., 2008; Kuchibhotla et al., 2009). However, because technical limitations have precluded examination of systems-level functional connectivity in model systems, the relationship between intrinsic functional connectivity, Aβ plaque deposition and normal aging in mouse brain remains unclear. Given these limitations, we designed a novel functional connectivity optical intrinsic signal (fcOIS) imaging approach (White et al., 2011) wherein changes in reflected light intensity from the surface of the brain are converted to changes in local hemoglobin concentration and used to measure intrinsic functional connectivity. Herein, we utilize fcOIS to determine whether the magnitude of regional bilateral functional connectivity prior to plaque deposition is indicative of subsequent region-specific Aβ plaque deposition. Additionally, we examine whether Aβ plaque deposition or normal aging is associated with functional connectivity disruption in APP<sup>swe</sup>/PS1<sup>ΔE9</sup> (APP/PS1) transgenic and wild-type mice, respectively.
MATERIALS AND METHODS

Animals. Male APPswe/PS1ΔE9 mice on a B6C3 background [APP/PS1(Jankowsky et al., 2004)] and B6C3 wild-type mice (The Jackson Laboratory) were aged to 3.0 ± 0.5 or 11.5 ± 0.5 months of age for experimentation. Mice were given ab libitum access to food and water. All experimental protocols were approved by the Animal Studies Committee at Washington University.

Animal preparation. In accord with our previously published animal preparation protocol for fcOIS imaging (White et al., 2011), all mice were anesthetized with ketamine-xylazine and allowed 15 minutes for anesthetic transition. In order to achieve a equivalent depth of anesthesia across groups (as assessed by responsiveness to hind paw pinch, anesthesia duration, respiratory rate, and heart rate), mice were administered the following doses of 86.9 mg/kg ketamine, 13.4 mg/kg xylazine: 3 month-old APP/PS1, 1X; 11.5 month-old APP/PS1, 1.25X; all wild-type, 1.5X. Once induced, the animal was placed on a heating pad maintained at 37°C via feedback from a rectal probe (mTCII, Cell Microcontrols) and its head secured in a stereotactic frame using a nose cone and ear bars. Scalp fur was shaved and cleaned, a midline incision was made along the top of the head and the scalp was reflected, exposing approximately 1 cm² of the skull. The skull of each mouse was left intact and kept moist via application of mineral oil prior to the first imaging session. Forty-five minutes of data were collected for 36 out of 37 imaging sessions, with each imaging session consisting of consecutive five-minute data sets. Anesthesia duration was approximately 70 minutes for all groups. Respiratory rate during imaging sessions was monitored to be 3-4 Hz for all groups. Heart rate (measured by Fourier analysis of the OIS time-courses collected from each mouse brain during
imaging sessions) was similar across all groups (3 month-old APP/PS1, 3.3 ± 0.4 Hz; 11.5 month-old APP/PS1, 4.2 ± 0.3 Hz; 3 month-old wild-type, 3.9 ± 0.2 Hz; 11.5 month-old wild-type, 4.4 ± 0.3 Hz).

**Imaging system.** Sequential illumination was provided at four wavelengths by a ring of light emitting diodes (LEDs) placed approximately 10 cm above the mouse's head. Diffuse reflected light was detected by a cooled, frame-transfer EMCCD camera (iXon 897, Andor Technologies); the LED ring and the camera were time-synchronized and controlled via computer using custom-written software (MATLAB, Mathworks) at a full frame rate of 30 Hz. The secured mouse was placed at the focal plane of both the camera and the LED ring and held in place with a stereotactic holder. The field-of-view was adjusted to be approximately 1 cm² square for each mouse resulting in images covering the majority of the convexity of the cerebral cortex.

**Image processing.** Data from all mice were subject to an initial quality check prior to spectroscopic analysis. Data runs (5 minutes) in which reflected light level intensity (mean value over the brain) varied as a function of time by greater than 1% for any wavelength were discarded and excluded from further analysis. This preliminary analysis resulted in 15–45 minutes of data per mouse. For subsequent analysis, image light intensity at each wavelength was interpreted using the Modified Beer-Lambert Law, usually written as: \( \Phi(r,t) = \Phi_0 \cdot \exp(-\Delta\mu_a(r,t) \cdot L) \). Here, \( \Phi(r,t) \) is the measured light intensity, \( \Phi_0 \) is the baseline light intensity, \( \Delta\mu_a(r,t) \) is the change in absorption coefficient due to hemodynamic changes, and \( L \) is the optical path length factor for photons in the tissue [calculated from Eqn. 34 as described (Arridge et al., 1992)]. As there is no pre-stimulus baseline in resting-state experimentation, we instead normalized
relative to the average light intensity at each pixel, resulting in differential measures of absorption at each wavelength: \( \Delta \mu_{a,\lambda}(r,t) = -\ln(\Phi_{a,\lambda}(r,t)/\langle \Phi_{0a,\lambda}(r,t) \rangle)/L_\lambda \). Absorption coefficient data were converted to hemoglobin concentration changes by inverting the system of equations, \( \Delta \mu_{a,\lambda}(r,t) = E_{\lambda,i} \Delta [Hb_i](r,t) \) (where \( E \) is the extinction coefficient matrix (Prahl, 2002), and \( i \) runs over hemoglobin species). This inversion was performed using least-squares methods, yielding changes in oxy- and deoxy-hemoglobin at each pixel at each time point.

Since previous functional connectivity studies with diffuse optical tomography (White et al., 2009) showed similar maps using either HbO\(_2\) or Hb\(_R\) contrast, here we used only \( \Delta \text{HbO}_2 \) data for the connectivity analyses. Data were filtered to the functional connectivity band (0.009-0.08 Hz) following previous human functional connectivity algorithms (Fox et al., 2005). After filtering, each pixel's time series was resampled from 30 Hz to 1 Hz, and all further analysis was performed only on those pixels labeled as brain. This procedure is necessary as every mouse's head is shaped differently, and the view of the brain exposed varied slightly between surgeries. Time traces of all pixels defined as brain were averaged to create a global brain signal. This global signal was regressed from each pixel's time trace to remove global sources of variance, as is common in human fMRI algorithms.

**Seed-based functional connectivity measures.** To investigate the strength of network correlations, we focused on bilateral connectivity between homotopic areas in contralateral hemispheres. Twelve seed locations were positioned at coordinates expected to correspond to the left and right, frontal, cingulate, motor, somatosensory, retrosplenial and visual cortices as described previously (White et al., 2011). Seed time-traces for the
full data sets of each mouse (ranging from 15 to 45 minutes) were calculated by averaging the time traces within 0.25 mm of the seed locus (containing approximately 30 pixels) of each seed location. Functional connectivity analysis was performed by correlating these time courses against the time course of every pixel in the brain. This procedure produces twelve functional connectivity maps over the mouse brain (one map per seed). These functional connectivity maps were then compressed to a 12x12 seed-to-seed correlation matrix by correlating each of the 12 seed time traces. Pearson $r$ values were converted to Fisher $Z$ measures using: $Z(r) = \text{arctanh}(r)$.

The above seed-to-seed correlation approach evaluates the functional connectivity between only six regions of the brain. To further examine the bilateral connectivity across the entire brain of each group of mice, 15 min of data were used from every mouse by concatenating three randomly chosen, five-minute sequences out of a mouse's data set. Each frame of the 15-minute image sequence (as well as the brain mask for that mouse) was then affine-transformed to a common atlas space (Franklin and Paxinos, 1996) determined by the positions of the junction between the coronal suture and sagittal suture (posterior to the olfactory bulb and cerebrum along midline) and the position of lambda. The stretch component for the anterior-posterior stretch was set equal to the medial-lateral stretch. The intersection of the brain masks from all mice was calculated and made symmetric by reflection across the midline allowing all subsequent comparisons across mice to be performed only on brain areas shared between all mice.

To create the bilateral connectivity maps (Fig. 6), the 15-minute data sets from all mice within a group were concatenated following transformation to create four larger data sets. Every pixel was then used as a seed (which had a time trace consisting of the
average of the 30 pixels around it as described above) and correlated against its corresponding contralateral pixel, resulting in a symmetric map of correlation strengths for each cohort.

**Aβ plaque deposition.** Animals were transcardially perfused with chilled phosphate-buffered saline (PBS, pH 7.4) with 0.3% heparin immediately following the final fcOIS session. Brains were removed and postfixed in 4% paraformaldehyde at 4°C overnight. Following fixation, brains were cryoprotected in 30% sucrose in PBS at 4°C for 72 hours. Using a freezing sliding microtome (Microm), serial coronal sections (50-µm section thickness) were collected from frontal cortex to caudal hippocampus. Sections (each separated by 300 µm) were stained with biotinylated HJ3.4 (anti-Aβ1-13, mouse monoclonal antibody generated in-house) to visualize Aβ immunopositive plaques. Immunostained sections were scanned using a Nanozoomer slide scanner (Hamamatsu Photonics). Quantitative analysis of percentage area covered by immunopositive staining was performed as described previously (Kim et al., 2009b). Briefly, images of immunostained sections were exported with NDP viewer (Hamamatsu Photonics), converted to 8-bit grayscale using ACDSee Pro 2 software (ACD Systems), thresholded to highlight Aβ-specific staining and analyzed using Image J software (National Institutes of Health). A mouse brain atlas (Franklin and Paxinos, 1996) was used to identify frontal, motor, somatosensory, cingulate, retrosplenial and visual cortices for quantitative analysis of Aβ immunopositive staining.

**Statistical analysis.** Statistical significance was determined by two-tailed t-test if two groups were compared. When variance differed significantly between groups, Welch’s t-test was used. One-way ANOVA followed by Tukey’s post hoc test for multiple
comparisons were used when more than two groups were compared. All statistical analyses were performed using Prism version 5.00 for Windows (GraphPad). Values were accepted as significant if $P < 0.05$. 
RESULTS

Bilateral functional connectivity magnitude predicts region-specific Aβ plaque deposition

In human brain, there exists a striking spatial correlation between areas of elevated resting-state functional connectivity in cognitively normal adults and the topography of Aβ plaque deposition in AD (Buckner et al., 2009). To examine the relationship between intrinsic functional connectivity and Aβ plaque deposition in mouse brain, we utilized a novel fcOIS imaging approach to characterize the magnitude of bilateral functional connectivity in multiple brain systems of young (3.0 ± 0.5 months of age) APP/PS1 mice prior to the onset of plaque deposition. Seed-based time traces of ΔHbO₂ concentration in each region-of-interest were calculated and correlated with every pixel in the brain (Fig. 1A-F). We found that the magnitude of bilateral functional correlation in young APP/PS1 mouse brain was greatest in retrosplenial cortex (z(r), 1.4 ± 0.16), intermediate in cingulate (0.96 ± 0.9), frontal (0.74 ± 0.06) and motor (0.99 ± 0.13) cortices, and low in somatosensory (0.49 ± 0.06) and visual (0.6 ± 0.15) cortices (Fig. 1G; n = 7). A similar pattern of regional functional connectivity magnitude was observed in agematched wild-type mice, suggesting that regional differences in bilateral functional connectivity are intrinsic to normal brain physiology (n = 13; Fig. 2).

To determine whether regional bilateral functional connectivity magnitude in young APP/PS1 mice prior to plaque deposition was indicative of the regional vulnerability to Aβ plaque deposition in older APP/PS1 mice, we next characterized the distribution of Aβ immunopositive plaque deposition in older (11.5 ± 0.5 months of age)
APP/PS1 mouse brain. Brain sections were immunostained with biotinylated HJ3.4 antibody, to Aβ amino acids 1-13 (anti-Aβ1-13) to determine the percentage area occupied by Aβ plaques in each region-of-interest (Fig. 3A-D). We found that Aβ plaque deposition was greatest in retrosplenial cortex (18.01% ± 3.86), intermediate in cingulate (9.04 ± 2.97), frontal (6.63 ± 1.63), motor (7.26 ± 1.38) cortices, and low in somatosensory (3.74 ± 0.75) and visual (5.16 ± 0.69) cortices (Fig. 2E; n = 4). Bilateral functional connectivity magnitude in young APP/PS1 mice prior to plaque deposition was thus proportional to the amount of Aβ plaque deposition in older APP/PS1 mice in a region-specific manner (Fig. 3F).

**Aβ plaque deposition and normal aging are associated with functional connectivity disruption**

Amyloid plaque deposition is associated with reduced resting-state functional connectivity in patients with AD (Supekar et al., 2008; Zhang et al., 2009) and cognitively normal adults who harbor significant amyloid load (Hedden et al., 2009; Sheline et al., 2010a; Drzezga et al., 2011). Therefore, we utilized fcOIS to determine whether Aβ plaque deposition was associated with decreased functional connectivity in older (11.5 ±0.5 months of age) APP/PS1 mice. Relative to 3 month old APP/PS1 mice, 11.5 month old APP/PS1 mice exhibited significant reductions in bilateral functional correlation strength in frontal (z(r), 0.49 ±0.08; P = 0.0298), motor (0.48 ± 0.15; P = 0.0217), cingulate (0.58 ± 0.13; P = 0.0312) and retrosplenial (0.46 ± 0.06; P = 0.0009) cortices. No significant differences were observed in somatosensory (0.32 ± 0.12; P = 0.2266) or visual (0.21 ± 0.1; P = 0.0571) cortices (Fig. 4A-G; n = 7).
In humans, normal aging is associated with disruption of functional connectivity in multiple brain areas (Andrews-Hanna et al., 2007). We thus sought to determine whether normal aging was associated with reduced bilateral connectivity in older (11.5 ± 0.5 months old) B6C3 wild-type mice. Compared to young B6C3 wild-type mice, 11.5 month old wild-type mice exhibited a significant reduction in bilateral connectivity in retrosplenial cortex (z(r), young, 1.1 ± 0.06; 11.5 month, 0.69 ± 0.07; P = 0.0002). In contrast, comparisons of bilateral functional connectivity between young and 11.5 month old wild-type mice were not significant in frontal (young, 0.81 ± 0.1; 11.5 month, 0.71 ± 0.09; P = 0.4554), motor (young, 0.68 ± 0.07; 11.5 month, 0.83 ± 0.14; P = 0.2954), somatosensory (young, 0.45 ± 0.11; 11.5 month, 0.67 ± 0.08; P = 0.1438), cingulate (young, 0.99 ± 0.09; 11.5 month, 1.0 ± 0.09; P = 0.9370) or visual (young, 0.42 ± 0.08; 11.5 month, 0.52 ± 0.1; P = 0.4383) cortex (Fig. 5A-G; n = 10–13/group).

To more closely examine the spatial relationship between Aβ plaque deposition and age-related decline in bilateral functional connectivity in APP/PS1 mice, an equal number of fcOIS data sets from each mouse were affine-transformed to a common atlas space and concatenated before calculating the correlation between each bilateral pixel set in the brain. Thus, a single full-field consensus bilateral connectivity map was generated for each cohort (Fig. 6A,B,D,E). Notably, the consensus bilateral connectivity maps generated for each cohort qualitatively reproduce the regional differences in bilateral functional connectivity magnitude reported above. To examine pixel-wise, age-related changes in bilateral functional connectivity magnitude, bilateral correlation consensus values generated from older mice were subtracted from bilateral correlation consensus values generated from young mice of the same genotype. The resultant difference maps
reveal regional differences in the level of age-related functional decline in APP/PS1 (Fig. 6C) and wild-type (Fig. 6F) mice. In APP/PS1 mice, age-related decline in functional connectivity was greatest in retrosplenial cortex and lowest in somatosensory cortex (Fig. 6C). As the level of plaque deposition in older APP/PS1 mice was greatest in retrosplenial cortex and lowest in somatosensory cortex, this finding suggests that the amount of regional plaque deposition is linked with the level of age-related decline in local bilateral functional connectivity. In wild-type mice, retrosplenial cortex exhibited the greatest age-related decline in functional connectivity while subtle increases in bilateral functional correlation were observed in motor and somatosensory cortices (Fig. 6F). Together, these data suggest that bilateral functional connectivity in mouse brain is reduced in normal aging and is markedly exacerbated by Aβ accumulation in the brain in a region-specific pattern.
DISCUSSION

In human brain, there exists a striking spatial correlation between areas that exhibit disproportionately high resting-state functional connectivity in cognitively normal adults and the distribution of amyloid plaque deposition in AD (Buckner et al., 2009). Moreover, functional connectivity is decreased in AD and cognitively normal individuals who harbor elevated amyloid deposition (Supek et al., 2008; Hedden et al., 2009; Zhang et al., 2009; Sheline et al., 2010a; Drzezga et al., 2011). Thus, elucidating the mechanisms that underlie the relationship between functional connectivity and Aβ plaque deposition may inform AD pathobiology and potentially reveal novel therapeutic avenues. However, as the small size of mouse brain necessitates an exceptionally high signal-to-noise ratio to achieve sufficient spatial resolution for functional magnetic resonance imaging, the relationship between functional connectivity and Aβ plaque deposition in mouse brain has remained unknown. Here, we utilize a novel fcOIS imaging approach (White et al., 2011) to characterize the relationship between functional connectivity, Aβ plaque deposition, and normal aging in mouse brain. We found that bilateral functional connectivity magnitude varied significantly across brain regions of young APP/PS1 mice and that the magnitude of region-specific bilateral functional correlation in young APP/PS1 mice prior to the onset of Aβ plaque formation was proportional to the density of regional plaque deposition in older APP/PS1 mice. This finding is consistent with human data suggesting that heteromodal association areas of the default-mode network exhibit disproportionately high intrinsic structural and functional connectivity in cognitively normal young adults and are among the brain regions most vulnerable to Aβ deposition in AD (Hagmann et al., 2008; Buckner et al.,
Importantly, as shown here, this OIS imaging approach combined with mouse models of neurodegeneration should allow for novel insights with regard to the role of specific genes/proteins in systems-level neural function. Several reports have demonstrated that functional connectivity is impaired in AD and in cognitively normal elderly harboring significant amyloid plaque burden (Supekar et al., 2008; Hedden et al., 2009; Zhang et al., 2009; Sheline et al., 2010a; Drzezga et al., 2011). In accord with these human data, the present findings suggest that region-specific Aβ accumulation is associated with significant reductions in bilateral functional connectivity magnitude in multiple brain systems of older APP/PS1 mice. Moreover, we observed that brain regions in which amyloid deposition was most prominent (e.g. retrosplenial cortex) exhibited greater age-related declines in functional connectivity relative to areas of lesser plaque deposition (e.g. somatosensory cortex). As Aβ plaque deposition is associated with local neuritic dystrophy and impaired synaptic integration in APP transgenic mice (Knowles et al., 1999; D'Amore et al., 2003; Lombardo et al., 2003; Tsai et al., 2004; Brendza et al., 2005; Garcia-Alloza et al., 2006; Meyer-Luehmann et al., 2008) future application of fcOIS will permit examination of the molecular mechanisms that underlie the relationship between Aβ plaque deposition and impaired systems-level functional connectivity.

In humans, normal age-related memory deficits are associated with decreased functional correlation between medial prefrontal cortex and posterior cingulate/retrosplenial cortex (Andrews-Hanna et al., 2007). Here, we found that retrosplenial cortex exhibits decreased bilateral functional connectivity in wild-type mice at 11.5 months of age. As age-related memory deficits are not present in wild-type mice
at this age, and given that retrosplenial cortex is important for learning and memory (Keene and Bucci, 2008, 2009; Corcoran et al., 2011), impaired bilateral functional connectivity in retrosplenial cortex may represent an early event in age-related neural dysfunction that ultimately results in memory impairment. In this context, fcOIS may serve as a useful tool to investigate the molecular mechanisms that contribute to decreased functional connectivity and memory dysfunction associated with normal aging.

Our laboratory has recently demonstrated that regional differences in endogenous neuronal activity are closely associated with interstitial fluid Aβ levels and are a key determinant of region-specific Aβ plaque deposition in APP transgenic mice (Bero et al., 2011). As the present data suggest that regional bilateral functional connectivity magnitude in young mice prior to plaque deposition is also associated with the level of subsequent Aβ plaque deposition, it will be important to examine the relationship between neuronal population activity and systems-level functional connectivity and how these mechanisms may independently or coordinately regulate Aβ metabolism.

A major challenge facing the neuroscience community is the paucity of clinically translatable assays that examine neural network function and integrity. Given that resting-state functional connectivity measures have provided valuable information regarding the functional organization of human brain (Fox and Raichle, 2007) and have yielded examples of how such organization is disrupted in disease (Zhang and Raichle, 2010), use of fcOIS in combination with genetic and molecular manipulations in mouse models provides an translational opportunity to elucidate mechanisms that underlie intrinsic functional connectivity in healthy brain and its disruption in models of neurological and neurodegenerative disorders. The clinically translatable nature of fcOIS
also positions this technique as a useful tool with which to examine the efficacy of pharmacological or behavioral interventions aimed to restore neural network integrity in such mouse models.
Figure 1. fcOIS reveals regional differences in bilateral functional connectivity magnitude in APP/PS1 mice prior to Aβ plaque deposition. A-F, Representative seed-based functional correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC; C), cingulate (CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 3.0 ± 0.5 month-old APP/PS1 mice. Black circles denote seed position and size. Scale, Pearson $r = -1$ to 1. G, Fisher z-transformed correlation values of bilateral functional correlation magnitude in each region of interest ($n = 7$/group). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ (one-way analysis of variance (ANOVA), Tukey’s post hoc test for multiple comparisons). Values represent mean ± s.e.m.
Figure 2. fcOIS reveals regional differences in bilateral functional connectivity magnitude in young wild-type mice. A-F, Representative seed-based functional correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC; C), cingulate (CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 3.0 ± 0.5 month-old wild-type mice. Black circles denote seed position and size. Scale, Pearson $r = -1$ to 1. G, Fisher z-transformed correlation values of bilateral functional correlation magnitude in each region of interest ($n = 13$/group). *, $P < 0.05$; ***, $P < 0.001$ (one-way analysis of variance (ANOVA), Tukey’s post hoc test for multiple comparisons). Values represent mean ± s.e.m.
Figure 3. Regional bilateral functional connectivity magnitude in young APP/PS1 mice is closely associated with regional plaque load in older APP/PS1 mice.  

$\begin{align*}
&\text{A} - \text{D, } \\
&\text{Representative brain sections from aged (11.5 ± 0.5 month-old) APP/PS1 mice stained with biotinylated HJ3.4 antibody (anti-Aβ$_{1-13}$) to visualize Aβ immunopositive plaques. Scale bar, 500 µm. } \\
&E, \text{ Percentage area occupied by Aβ deposition in frontal (FC), motor (MC), somatosensory (SC), cingulate (CC), retrosplenial (RC) and visual (VC) cortices (} n = 4 \text{ per group). } \\
&F, \text{ Fisher } z \text{-transformed correlation values of bilateral functional correlation magnitude in frontal (▲), motor (Δ), somatosensory (■), cingulate (○), retrosplenial (●) and visual (□) cortex of young APP/PS1 mice, plotted against subsequent Aβ plaque deposition in each brain region of aged APP/PS1 mice. } *
\end{align*}$
0.05; **, $P < 0.01$ (one-way ANOVA, Tukey’s post hoc test for multiple comparisons).

Values represent mean ± s.e.m.
Figure 4. Aβ plaque deposition is associated with decreased functional connectivity magnitude in multiple brain systems of older APP/PS1 mice. A-F, Representative seed-based functional correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC; C), cingulate (CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 11.5 ± 0.5 month-old APP/PS1 mice. Black circles denote seed position and size. Scale, Pearson $r = -1$ to 1. G, Fisher $z$-transformed correlation values of bilateral functional correlation magnitude in each region of interest in young (black bars) and older (white bars) APP/PS1 mice ($n = 7$/group). *, $P < 0.05$; ***, $P < 0.001$ (one-way ANOVA, Tukey’s post hoc test for multiple comparisons). Values represent mean ± s.e.m.
Figure 5. Normal aging is associated with decreased functional connectivity magnitude in retrosplenial cortex. A-F, Representative seed-based functional correlation maps of frontal (FC; A), motor (MC; B), somatosensory (SC; C), cingulate (CC; D), retrosplenial (RC; E) and visual (VC; F) cortices in 11.5 ± 0.5 month-old wild-type mice. Black circles denote seed position and size. Scale, Pearson $r = -1$ to 1. G, Fisher z-transformed correlation values of bilateral functional correlation magnitude in each region of interest in young (black bars) and older (white bars) wild-type mice ($n = 10–13$/group). ***, $P < 0.001$ (one-way ANOVA, Tukey’s post hoc test for multiple comparisons). Values represent mean ± s.e.m.
Figure 6. **Regional Aβ plaque deposition is associated with degree of age-related decline in bilateral functional connectivity.**  


Scale in *A,B,D,E*, Fisher z = -1.4 to 1.4.  Note that in *C,F*, positive values represent age-related decline, while negative values represent age-related increase, in bilateral functional connectivity magnitude.
Chapter 5.

Conclusions and future directions
Summary

As amyloid plaque deposition is a necessary event in AD pathogenesis, we sought to elucidate the factors that regulate cerebral amyloid plaque growth in vivo (Chapter 2 of this dissertation). Using intravital multiphoton microscopy through a thinned-skull cranial window in APP/PS1 bitransgenic mice, we found that amyloid plaques present in cortex of 6 month-old APP/PS1 mice exhibited significant growth over a period of weeks, while significant amyloid plaque growth was not present in 10 month-old APP/PS1 mice. In contrast, plaques imaged through an open-skull cranial window did not exhibit significant growth at either age, likely due to increased cortical gliosis in open-skull window preparations. Under thinned-skull window preparations, plaque growth rate was inversely proportional to initial plaque size in 6 and 10 month-old mice. Amyloid plaque formation and growth were prevented by pharmacological γ-secretase inhibition. In vivo microdialysis experiments performed in young APP/PS1 mice showed that reduction of ISF Aβ levels by 20-25% over the course of 24 hours was associated with a dramatic reduction in amyloid plaque formation and growth. Together, these data suggest that amyloid plaque formation and growth in vivo occurs over weeks and is closely related to animal age, initial plaque size and ISF Aβ concentration.

Though region-specific deposition of Aβ plaques is a fundamental feature of AD, the mechanisms that regulate the regional vulnerability to Aβ plaque deposition in AD remain unknown. We sought to address this issue in Chapter 3 of this dissertation. Using in vivo microdialysis, we found that the steady-state concentrations of ISF Aβ_{40} and Aβ_{42} in young Tg2576 mice prior to the onset of plaque deposition were closely associated with the spatial distribution of Aβ deposition in aged mice. We found that ISF lactate...
level was a valid marker of neuronal activity in vivo and that regional ISF lactate levels in young Tg2576 mice were closely associated with regional ISF Aβ levels and subsequent region-specific Aβ and amyloid plaque deposition. We found that region-specific Aβ plaque deposition was not predicted by ISF Aβ clearance rate, full-length APP expression or APP processing. To determine whether physiological neuronal activity directly regulates ISF Aβ levels, we used in vivo microdialysis to determine the effect of unilateral vibrissal trimming or stimulation on ISF Aβ levels in contralateral barrel cortex of young Tg2576 mice. We found that unilateral vibrissal trimming acutely reduced, and unilateral vibrissal stimulation acutely increased, ISF Aβ levels in contralateral barrel cortex. Using multiphoton microscopy, we found that long-term unilateral vibrissal trimming significantly reduced amyloid plaque formation and growth in contralateral barrel cortex. The results presented in Chapter 3 thus suggest that regional differences in steady-state neuronal activity regulate region-specific Aβ plaque deposition through long-term modulation of ISF Aβ concentration.

In Chapter 4, we sought to examine the relationship between functional connectivity, Aβ plaque deposition and normal aging in mouse brain. As technical limitations have heretofore precluded examination of systems-level functional connectivity in mouse brain, we utilized a novel fcOIS technique (White et al., 2011) to conduct the first study of systems-level functional connectivity in a mouse model of neuropathology or normal aging. We found that regional differences in bilateral functional connectivity magnitude were present in young APP/PS1 and wild-type mice. Interestingly, bilateral functional connectivity magnitude in young APP/PS1 mice was proportional to region-specific Aβ plaque deposition in aged APP/PS1 mice. The
relationship between functional connectivity and Aβ plaque deposition appeared to be bidirectional, as we found that Aβ deposition was associated with marked reductions in bilateral functional connectivity magnitude in several brain systems of aged APP/PS1 mice. In wild-type mice, normal aging was associated with a specific decrease in bilateral functional connectivity in retrosplenial cortex. Finally, we found that the degree of regional functional connectivity decline in aged APP/PS1 mouse brain was associated with the amount of region-specific Aβ plaque deposition. These data suggest a close relationship between functional connectivity, Aβ deposition and normal aging in mouse brain and provide a foundation for future investigation of the molecular mechanisms that underlie systems-level neural network dysfunction.
Super-resolution examination of AD pathogenesis

Since the seminal work of Santiago Ramón y Cajal, microscopic analysis of brain tissue has yielded fundamental insights into brain structure, function and the mechanisms by which pathological insults disrupt neural integrity. Until recently however, the diffraction limit of light has prevented molecular-level visualization of specific biomolecules in tissue sections. The advent of super-resolution fluorescence microscopy techniques such as stochastic optical reconstruction microscopy (STORM) now permits nanometer level examination of specific molecules in biological samples (Dani and Huang, 2010; Dani et al., 2010).

In Chapter 3 of this dissertation, we found that regional differences in steady-state neuronal activity regulate brain region-specific ISF Aβ levels and amyloid plaque growth dynamics in vivo. However, the mechanisms that regulate intrinsic differences in regional neuronal activity remain unclear. As synaptic vesicle exocytosis is necessary for neuronal activity-dependent Aβ secretion (Cirrito et al., 2005), molecular-level examination of synaptic protein expression across brain regions may provide valuable insights into the mechanisms that regulate region-specific Aβ plaque deposition. To this end, we have begun to use STORM to quantify markers of synapse density and neurotransmitter receptor composition (including GluR1, GluR1-Ser831-P, NR2A and CamKII-P) across cortical regions that exhibit differential susceptibility to Aβ plaque deposition. We hypothesize that synapse density and neurotransmitter receptor expression density in each brain region of young APP transgenic mice prior to the onset of plaque deposition will be proportional to the amount of region-specific Aβ plaque deposition in aged APP transgenic mice. Our in vivo microdialysis data suggest that
regional differences in neuronal activity present in young APP transgenic mice are similar to those present in wild-type mice (Chapter 3 of this dissertation). Using STORM, we will also examine synapse density and neurotransmitter receptor expression across brain regions of young wild-type mice to determine whether regional differences in synaptic architecture present in young APP transgenic mice are intrinsic to normal brain physiology or are affected by overproduction of full-length APP or APP cleavage derivatives such as Aβ.

It is well-established that Aβ plaque deposition is associated with synaptic loss in AD brain (Terry et al., 1991; Coleman and Yao, 2003) and mouse models of Aβ deposition (Koffie et al., 2009). However, technical limitations have heretofore precluded molecular-level examination of the effect of Aβ deposition on synaptic architecture in intact tissue. Therefore it will be of interest to use STORM to image synaptic protein expression in brain sections from aged APP transgenic mice that harbor Aβ plaque deposition and age-matched wild-type controls to examine whether Aβ deposition is associated with reduced local synapse density and neurotransmitter receptor expression. Anti-Aβ immunotherapy has been shown to prevent and remove cerebral Aβ deposition in APP transgenic mice (Schenk et al., 1999; Bard et al., 2000; Wilcock et al., 2004; Brody and Holtzman, 2008). Therefore, if Aβ plaque deposition is found to be associated with local reductions in synapse density and neurotransmitter receptor expression, a potential follow-up experiment would be to determine whether systemic anti-Aβ immunotherapy can prevent or reverse synaptic disruption in aged APP transgenic mice.
Moreover, STORM could be used to determine whether regional differences in the level of synaptic structural disruption are present in aged APP transgenic mice. If regional differences in synaptic disruption are present in aged APP transgenic mice, this result would provide an opportunity to link molecular-level structural disruption with systems-level functional dysfunction by examining whether the degree of molecular-level synaptic structural disruption in each brain region assessed by STORM is proportional to the degree of bilateral functional connectivity disruption in aged APP transgenic mice assessed by fcOIS.

**Mechanisms of functional connectivity disruption in AD**

Using a novel fcOIS approach, we found that Aβ plaque deposition is closely associated with region-specific functional connectivity decline in APP/PS1 mouse brain (Chapter 4 of this dissertation). As the experiments described in Chapter 4 were designed to determine whether Aβ plaque deposition was spatially correlated with decreased functional connectivity magnitude, whether Aβ aggregation is directly responsible for the observed functional connectivity decline in aged APP/PS1 mice remains unclear. Therefore, we have begun experiments to test whether systemic passive anti-Aβ immunotherapy in Tg2576 mice prior to the onset of robust plaque deposition prevents functional connectivity decline relative to vehicle-treated, age-matched Tg2576 mice. Since systemic anti-Aβ immunotherapy has also been suggested to clear existing Aβ plaques from the brain, one potential follow-up experiment would be to begin anti-Aβ immunotherapy in Tg2576 mice that harbor robust plaque deposition to determine whether Aβ plaque removal rescues functional connectivity dysfunction once significant Aβ plaque deposition has occurred.
Since AD is characterized by the presence of multiple neuropathological hallmarks, including amyloid plaque deposition, tau hyperphosphorylation and neurofibrillary tangle formation, one limitation of functional neuroimaging experiments in AD patients is the inability to attribute functional deficits to specific components of the disease process. However, given that we have recently utilized fcOIS to perform the first systems-level functional connectivity experiments in a mouse model of neuropathology (Chapter 4 of this dissertation), it is now possible to examine neural network function in transgenic mice that model specific neuropathological components of the AD process. In this context, it would be of interest to utilize fcOIS to examine whether tau hyperphosphorylation or neurofibrillary tangle formation is associated with decreased functional connectivity magnitude in a transgenic mouse model of tauopathy such as P301S (Yoshiyama et al., 2007). Although a comprehensive examination of regional differences in tau hyperphosphorylation and intracellular inclusion formation in P301S mice has not yet been performed, available data suggest that this model harbors relatively severe tau pathology in hippocampus and select cortical regions. Given the dense projections of hippocampus to retrosplenial cortex (Wyss and Van Groen, 1992), bilateral functional connectivity magnitude may be particularly decreased in retrosplenial cortex of P301S mice. Data suggest that tau immunotherapy can reduce tau hyperphosphorylation and aggregation in a mouse model of tauopathy (Boutajangout et al., 2010). Thus, if tau hyperphosphorylation and neurofibrillary tangle formation are shown to be associated with decreased functional connectivity magnitude, it would be interesting to determine whether tau immunotherapy can prevent or reverse functional connectivity dysfunction in mouse models of tauopathy.
Differential regulation of Aβ clearance is widely hypothesized to represent a principle mechanism by which apoE isoforms differentially modulate susceptibility to AD (Castellano et al., 2011). Interestingly, human functional neuroimaging data suggest that resting-state and task-induce brain activation are upregulated in ε4 carriers relative to non-carriers prior to and following cerebral amyloid deposition (Bookheimer et al., 2000; Filippini et al., 2009). Moreover, functional connectivity abnormalities have been reported in cognitively normal ε4 carriers relative to noncarriers (Fleisher et al., 2009; Sheline et al., 2010b; Machulda et al., 2011) and human ε4 knock-in mice exhibit reduced excitatory synaptic transmission and reduced dendritic spine density in certain brain regions (Wang et al., 2005). Therefore, altered brain activity and functional connectivity may represent an additional mechanism by which ε4 modulates AD risk. In this context, it would be of interest to utilize fcOIS to determine whether human ε2, ε3 or ε4 knock-in mice exhibit differential functional connectivity magnitude in the absence of Aβ pathology and whether normal age-related changes in functional connectivity magnitude are altered in an isoform-dependent manner. Moreover, using APP transgenic mice crossed with human ε2, ε3 or ε4 knock-in mice (Bales et al., 2009), it would be interesting to determine whether apoE isoform-dependent differences in steady-state ISF Aβ levels present throughout life and resultant differences in Aβ plaque deposition in aged mice (Castellano et al., 2011) are associated with differential functional connectivity magnitude.
Concluding remarks

Brain region-specific deposition of extracellular Aβ plaques is a pathological hallmark of AD. However, the mechanisms that regulate the regional vulnerability to Aβ plaque deposition in AD remain unknown. In this thesis, we utilized mouse models of cerebral Aβ deposition to examine molecular, cellular and systems-level mechanisms that regulate brain region-specific Aβ accumulation and aggregation. We found that amyloid plaque formation and growth is closely related to ISF Aβ concentration and that local steady-state neuronal activity levels regulate region-specific ISF Aβ levels and Aβ plaque deposition in vivo. Using a novel fcOIS technique, we also provide the first examination of systems-level functional connectivity in a mouse model of neuropathology or normal aging. We found that regional bilateral functional connectivity magnitude in young mice prior to the onset of Aβ deposition was proportional to the amount of region-specific Aβ deposition in aged mice. Moreover, we found that normal aging, and to a greater extent, Aβ deposition, were associated with marked decreases in bilateral functional connectivity. Together, these findings advance our understanding of the mechanisms by which specific brain regions are rendered vulnerable to Aβ plaque deposition in AD and suggest that intrinsic brain metabolism and functional organization may contribute to AD pathogenesis.
References


Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of
transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945.


Fox MD, Raichle ME (2007) Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8:700-711.


